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Abstract 
Background: In the last decade, several new antihyperglycemic medications have been 
approved to treat people with diabetes. However, the hypoglycemia risk of these medications 
in older adults in routine clinical practice remains unclear. Further, there is limited 
understanding as to how these medications are being prescribed to older adults in our region.  
Methods: We carried out retrospective, population-based studies of adults age 66 and older 
in Ontario, Canada using linked healthcare databases. We first investigated the real-world 
hypoglycemia risk of 2 antihyperglycemic medications – glyburide and modified-release 
gliclazide. In an ecological study, we then examined trends in antihyperglycemic medication 
prescriptions, and in this setting, investigated hospital encounters for hypoglycemia.   
Results:  Initiating glyburide vs gliclazide as monotherapy or in the presence of metformin 
was associated with a significantly higher risk of a hospital encounter with hypoglycemia.  
Over the last decade, newer and safer antihyperglycemic medications have been prescribed to 
older adults in our region. In this setting, the overall percentage of patients with a hospital 
encounter with hypoglycemia has declined. 
Conclusions: Antihyperglycemic medications differ in their real-world hypoglycemia risk in 
older patients. In the setting of newer and safer antihyperglycemic medications, encounters 
for hypoglycemia have declined. 
Keywords 
Diabetes, hypoglycemia, older adults, antihyperglycemic medications, glyburide, modified-
release gliclazide 
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Chapter 1  
1 Introduction 
1.1 What is diabetes? 
Diabetes is a chronic metabolic condition characterized by insulin deficiency, impaired 
secretion and/or insulin resistance (ie poor utilization). As insulin aids in the storage and 
utilization of glucose,1,2 patients with diabetes have elevated blood sugar or 
hyperglycemia. The Canadian Diabetes Association currently recommends that a 
diagnosis of diabetes be made in an individual with: 1) a fasting blood glucose ≥7 
mmol/L, or 2) a 2 hour blood glucose ≥11.1 mmol/L following a 75 gram oral glucose 
tolerance test, or 3) a random blood glucose ≥11.1 mmol/L or 4) a glycosylated 
hemoglobin (HbA1c) greater than 6.5% (a test that reflects glycemic control over the 
previous  8-12 weeks).3  
There are two main types of diabetes - type 1 diabetes and type 2 diabetes. Type 1 
diabetes is the result of pancreatic beta-cell destruction, most commonly from an 
autoimmune process.4 This leads to insulin deficiency and these patients require insulin 
replacement therapy.1 Type 1 diabetes can occur at any age but is more common in 
childhood and adolescence. It accounts for approximately 5% of all patients with 
diabetes.2   
Type 2 diabetes is characterized by insulin resistance and impaired insulin secretion.2  
Although genetic factors play a role in its development, it is closely related to obesity and 
decreased physical activity.5 As such, these patients often have concomitant medical 
conditions including lipid disorders and high blood pressure (the “metabolic 
syndrome”).1 Most people with type 2 diabetes do not need insulin initially, but with 
time, often require it to maintain  adequate glycemic control.1 Type 2 diabetes typically 
arises in adulthood, though it is increasing in onset in younger individuals. It accounts for 
about 95% of patients with diabetes.2 
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1.2 What is the burden of diabetes? 
The number of people with type 1 and type 2 diabetes is increasing in North America and 
worldwide.4,6 In 2013 there were almost 2 million people over the age of 12 with the 
condition in Canada, and almost 900,000 were age 65 and older.7 Where sedentary habits 
and obesity are epidemic, this trend is expected to continue, especially in type 2   
diabetes.6  
Diabetes can lead to significant consequences for patients including structural 
complications, treatment related side effects, impaired quality of life, and premature 
death (detailed below). The disease is also associated with major economic burden, and 
has consumed an increasing proportion of provincial health care expenditures.8 From 
2000 until 2010, the economic burden of diabetes (direct and indirect costs) was 
estimated to double ($6.3 billion in 2000, $12.2 billion in 2010). By 2020, it has been 
projected that its associated costs will increase by another $4.7 billion.8 
1.3 What are the consequences of diabetes? 
Diabetes can have several significant consequences for patients. Acutely, hyperglycemia  
can lead to symptoms including frequent urination and blurred vision.1 Weight loss may 
occur through the depletion of water and nutrient stores, and dizziness and weakness can 
result from lowered plasma volume.1 In severe instances, diabetic ketoacidosis or  
hyperglycemic hyperosmolar state (ie. hyperglycemic emergencies) can arise which may 
lead to hospital presentation, morbidity and mortality.9 
Over the longer term, hyperglycemia can also result in small and large blood vessel 
damage. Small vessel damage, termed microvascular disease, typically impacts the 
kidney (nephropathy), nerves (neuropathy), and eyes (retinopathy). Diabetic nephropathy 
initially manifests as protein loss in the urine (proteinuria) and eventually can lead to 
chronic kidney disease.1 Neuropathy can involve the sensory, motor and autonomic 
nerves and can result in loss of vibration sense and temperature along with pain, impaired 
reflexes, joint and connective tissue changes, low blood pressure, impaired gastro-
intestinal activity (ie. gastroparesis), and bladder and erectile dysfunction.1 Diabetic 
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retinopathy can lead to vision loss as a result of hemorrhage, microaneurysms, exudates, 
retinal detachment and macular edema.1 
Chronic hyperglycemia can also lead to large vessel or macrovascular disease which 
impacts the vessels of the heart (cardiovascular), brain (cerebrovascular) and periphery 
(peripheral vascular). Cardiovascular disease may lead to heart attack and heart failure. 
Peripheral vascular disease may cause ischemia of the lower extremities, erectile 
dysfunction, intestinal angina and gangrene.1 Cerebrovascular disease may result in 
stroke or transient ischemic attack.   
Other recognized complications of diabetes include bony fractures,10 skin changes, and 
chronic infections.1 In the elderly, depression, impaired cognition, urinary incontinence 
and chronic pain have also been identified.11 Life expectancy is 3 to 6 years shorter in 
patients over the age of 65 with diabetes compared to those without the condition.11 
1.4 How is diabetes managed? 
The management of diabetes involves treating hyperglycemia and managing its related 
complications.12 
1.4.1 Hyperglycemia 
Central to the management of diabetes is controlling hyperglycemia. The target for 
glycemic control for most patients with diabetes is an HbA1c less than 7%. This is based 
upon studies which have indicated that an HbA1c less than 7% reduces the risk of 
microvascular complications, and in younger patients with a recent diagnosis of the 
disease, macrovascular complications.13–17  
Glycemic control can be accomplished through lifestyle modification and/or the initiation 
of antihyperglycemic medications. Lifestyle modification (including exercise, healthy 
diet, and weight control), can have a significant impact on blood sugars. In fact, for type 
2 diabetes, lifestyle changes are considered first line therapy. In a meta-analysis of the 
effects of exercise on glycemic control, it was found that aerobic, resistance and 
combination exercise programs improved glycemia.18 Likewise, nutritional therapy with 
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a registered dietitian can lower HbA1c by 1 to 2%.19 The impact of weight loss on 
glycemic control is supported by recent studies on the benefits of bariatric surgery in type 
2 diabetes .20 Physicians who treat diabetes usually aim for multi-factorial lifestyle 
intervention based upon the benefits reported by the Diabetes Prevention Program (DPP)  
Trial,21 and the LOOKAHEAD trial which indicated that patients randomized to an 
intensive lifestyle (healthy diet and 175 minutes of physical activity per week to induce at 
least 7% weight loss) had a lower HbA1c after 4 years compared to those randomized to 
diabetes support and education alone (HbA1c  -0.36% vs -0.09%, p<0.001).22 
Beyond lifestyle modification, antihyperglycemic medications can help to improve 
glycemic control. These medications can include insulin (for both type 1 and 2 patients) 
or other oral/subcutaneous antihyperglycemic medications (for patients with type 2 
diabetes). Where only sulphonylureas (eg. glyburide), biguanides (eg. metformin), 
insulin, and alpha glucosidase inhibitors (eg. acarbose) were available for the treatment of 
type 2 diabetes in Canada in the 1990’s, there are now 20 different antihyperglycemic 
medications approved for use in our country, each with different benefits and side effect 
profiles (list of available drugs, potency, side effects presented in Table 1). 
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Table 1. Antihyperglycemic medications currently available in Canada 
Class Drug Names 
Available 
Mechanism of 
Action 
 
Glucose 
Lowering 
Effect 
Weight 
Effect 
Hypoglycemic 
Risk 
Side Effects Notes 
Biguanides Metformin Decreases hepatic 
glucose output; 
enhances insulin 
effect at peripheral 
receptors 23 
Reduces 
HbA1c by 
1.5% 24 
Weight 
loss 
reported 25 
Negligible risk 
as monotherapy 6 
Gastrointestinal 
upset, lactic 
acidosis (esp in 
those with renal, 
liver, heart failure) 
6
 
Considered first 
line therapy for 
type 2 diabetes by 
most clinical 
practice guidelines 
Alpha glucosidase 
inhibitors 
Acarbose Inhibits the intestinal 
enzyme that breaks 
down polysaccharides 
and  reduces 
carbohydrate re-
absorption1 
Reduces 
HbA1c by 
0.5-0.8% 
24
 
Neutral Negligible risk 
as monotherapy 
23
 
Gastrointestinal 
upset 
 
Insulin Bolus: Aspart, 
Glulisine, Lispro, 
Regular 
Basal: NPH, 
Binds to receptor on 
surface of target cell 
membrane leading to 
increased glycogen, 
lipid and protein 
Reduces 
HbA1c by 
1.5-2.5% 
24
 
Associated 
with 
weight 
gain 24 
Very high risk of 
hypoglycemia 
 For treatment of 
type 1 and type 2 
diabetes.  Need 
consideration of 
patient function, 
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Detemir, Glargine 
Pre-mixed: 
Regular/NPH 
(30/70, 40/60, 
50/50), Biphasic 
aspart (novomix 30), 
Lispro/protamine 
(Humalog mix 25, 
50)26 
synthesis; triggers 
genes involved in 
growth and 
metabolism; promotes 
the storage of 
ingested nutrients1 
autonomy, 
cognition, vision, 
self-management 
ability. No dose 
ceiling and flexible 
regimens27 
Sulphonylureas Glyburide, 
Gliclazide, 
Glimepiride, 
Acetohexamide, 
Chlorpropamide, 
Tolbutamide 
Bind to sulphonylurea 
receptor on the beta 
cell of the pancreas to 
inhibit potassium 
efflux; leads to 
depolarization of beta 
cell and insulin 
release 25 
Reduces 
HbA1c by 
1.5%24 
Associated 
with 
weight 
gain 25 
High risk of 
hypoglycemia   
 Often considered 
second line agent 
to metformin in 
type 2 diabetes  
Thiazolidinediones Pioglitazone, 
Rosiglitazone 
Bind to perioxisome 
proliferator activated 
receptors; increase 
sensitivity of muscle 
fat, and liver to 
Reduce 
HbA1c by 
0.5 to 
1.4%24 
Weight 
neutral 
Negligible risk 
of hypoglycemia 
as monotherapy 
Edema, heart 
failure, fracture, 
hepatotoxicity. 
Rosiglitazone 
potentially linked 
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insulin1 to adverse 
cardiovascular 
events6,25 
Meglitinides Repaglinide, 
Nateglinide 
Bind to sulphonylurea 
receptor and induce 
the depolarization of 
pancreatic beta cells 
to secrete insulin23 
Reduce 
HbA1c by 
1-1.5%24 
Associated 
with 
weight 
gain6 
Risk of 
hypoglycemia 
(though less than 
with 
sulphonylureas) 
 Rapid onset of 
action so can be 
dosed prior to 
meals 
Dipeptidyl 
peptidase-4 
inhibitors 
Sitagliptin, 
Saxagliptin, 
Linagliptin 
Inhibit the enzyme 
degradation of 
glucagon like peptide- 
1; suppress glucose 
release, delays gastric 
emptying and 
stimulates insulin 
release from the 
pancreas in a glucose 
dependent fashion 25 
Reduce 
HbA1c by 
0.5-1%24 
Weight 
neutral 
Negligible risk 
of hypoglycemia 
as monotherapy 
Gastrointestinal 
upset, 
nasopharyngitis, 
headache 
 
Glucagon like 
peptide-1 agonists 
Exenatide, 
Liraglutide 
Glucagon like 
peptide-1 stimulates 
insulin release from 
the pancreas in a 
Reduce 
HbA1c by 
0.5 to 
1%24 
Associated 
with 
weight loss 
24
 
Negligible risk 
as monotherapy 
Gastrointestinal 
discomfort 
Subcutaneous 
injection 
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glucose dependent 
fashion23 
Sodium glucose co-
transporter  2 
inhibitors 
Canagliflozin, 
Dapagliflozin 
Inhibit renal 
reabsorption of 
glucose 28 
Reduce 
HbA1c by 
about 
0.7% 
Associated 
with 
weight loss 
Negligible risk 
as monotherapy 
Genital mycotic 
infections, osmotic 
diuresis and 
volume depletion 
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1.4.2 Diabetes-related complications 
In addition to managing hyperglycemia, physicians who treat diabetes must also address 
its related complications.   
Alongside tight glycemic control, kidney health can be optimized through control of 
blood pressure and the use of angiotensin converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers (ARB’ s).29–32 Eye health can be promoted through blood 
pressure control and smoking cessation.1 In those with advanced retinopathy, 
photocoagulation can reduce severe visual loss.1,33 Neuropathy-associated conditions 
including gastroparesis can be managed with medications including dopamine 
antagonists (eg. metoclopramide, domperidone) and erythromycin. Erectile dysfunction 
can be treated with cyclic guanosine monophosphate-specific phosphodiesterase type 5 
inhibitors.1,34 Painful diabetic neuropathy can be treated with anticonvulsants, 
antidepressants, opioids, topical nitrates, and capsaicin.34 
In addition to lifestyle modification, the cardiovascular health of patients can be 
optimized with smoking cessation,35 the use of lipid-lowering medications,36,37 the control 
of blood pressure,38 antiplatelet therapy (in those with a previous cardiovascular event or 
at high risk of an event),39 and ACE inhibitors or ARB’s.32,40,41  A multifactorial strategy 
to improve cardiovascular health is especially beneficial as illustrated by the STENO 2 
trial. In this trial, patients randomized to intensive therapy (ie. tight glucose control, ACE 
inhibitors or ARB’s, aspirin and lipid lowering therapy) had both a lower risk of death 
from cardiovascular causes (hazard ratio (HR) 0.43 [95% confidence interval (CI) 0.19 to 
0.95], p=0.04] and a lower risk of cardiovascular events (HR 0.41 [95% CI 0.25 to 0.67], 
p<0.001) compared with those randomized to standard care.42  
Finally foot health can be maintained through regular physical examination, education, 
the optimization of vascular health, the use of proper footwear, and early referral should 
foot complications occur.43 For those with evidence of skin ulcers, local wound care, 
debridement and mechanical unloading are important interventions.1,43 
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1.5 What are the complications of diabetes 
management? 
1.5.1 Hypoglycemia 
Because antihyperglycemic medications by design lower blood glucose levels, a 
significant complication of diabetes management is hypoglycemia. Though definitions 
vary, the Canadian Diabetes Association defines hypoglycemia by 1) the development of 
symptoms (eg. shaking, tremor); 2) a low plasma glucose level (<4.0 mmol/L); and 3) the 
relief of symptoms with carbohydrate administration.44 The severity of hypoglycemia is 
best defined by whether a patient can self-treat their episode with the ingestion of 
carbohydrate (mild) or if they need assistance for treatment from another person 
(severe).45  
In addition to producing uncomfortable symptoms including tremor, lightheadedness, 
palpitations, sweating, anxiety, hunger, nausea, tingling, vision changes, and headaches, 
44
 hypoglycemia can have other significant consequences for patients. 
Motor activities and coordination can be impacted leading to falls, injury and fracture.45  
Reaction times can also be prolonged and often do not return to baseline until 20-30 
minutes after normal blood glucose levels are restored.46 As a result, activities including 
driving performance can deteriorate. 
Hypoglycemia can also lead to neurological dysfunction including decreased level of 
consciousness, coma, stroke, transient ischemic attack and seizures.45 In the elderly there 
is additionally increasing evidence that recurrent exposure to severe episodes of 
hypoglycemia can have detrimental effects on cognitive function and may promote the 
development of dementia.45 In a study of 16,667 older patients with type 2 diabetes, the 
age-adjusted incidence rates of dementia were elevated for those with at least 1 severe 
hypoglycemic episode compared with those with no episodes (567 cases per 10,000 
person years [95% CI 497 to 637 per 10,000 person-years] vs 328 cases per 10,000 
person years [95% CI 311 to 343 per 10,000 person years], adjusted HR 1.68 [95% CI 
1.47 to 1.93]). In this study, the risk of dementia also increased with a greater number of 
hypoglycemic events.47 
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Additionally, the release of stress hormones in the setting of hypoglycemia can impact 
the cardiovascular system. In those with heart disease, hypoglycemia has been linked 
with heart attack, heart failure, and irregular heart rhythms.45  
Further, it has been recognized that hypoglycemia has a significant impact on quality of 
life. Barnett et al found that hypoglycemia was independently associated with reduced 
quality of life and additionally noted that the magnitude of the quality of life reduction 
increased with the severity and frequency of hypoglycemia symptoms.46 Events can also 
lead to adverse consequences in the work place, in social relationships and in the 
educational environment.45 
Hypoglycemia has also been associated with death. “Dead in bed syndrome” has been 
described in case reports of patients with type 1 diabetes with documented nocturnal 
hypoglycemia (by real-time glucose monitoring) who died in their sleep.46 In a case-
control study of hospitalized patients, it has also been found that insulin-associated and 
spontaneous hypoglycemia was associated with increased mortality.48 
Additional consequences of hypoglycemia include a fear of ongoing events which may 
prompt avoiding behaviour and poor adherence to diabetes treatment.45,46 Chronic 
hypoglycemia can also impair defenses against subsequent falling plasma glucose 
concentrations and may lead to a cycle of recurrent hypoglycemia.46 
1.5.2 Additional risk factors for hypoglycemia 
Beyond the use of antihyperglycemic medications, several risk factors have been 
established for hypoglycemia. Those with type 1 diabetes 45 and advanced type 2 diabetes 
46
 are at increased risk along with those with either tightly controlled or poorly controlled 
blood sugar.49,50 Compared with patients using thiazolidinediones, metformin, dipeptidyl 
peptidase-4 inhibitors (DPP-4), glucagon like peptide-1 agonists (GLP-1), and sodium 
glucose co-transporter 2 inhibitors (SGLT2), those using insulin, sulphonylureas and 
meglitinides are also at higher risk of hypoglycemia (Table 1).45   
Several comorbidities also place patients at increased risk of hypoglycemia. These 
include nephropathy, cognitive dysfunction, alcohol use, neuropathy and hypoglycemia 
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unawareness (impaired awareness of hypoglycemia symptoms).45 The elderly are at 
particular risk of hypoglycemia as they have impaired counter-regulatory responses,51 
tend to have few warning symptoms,51,52 and recover more slowly from events.45   
1.6 Special issues in older adults and the need for 
research 
Glycemic control is a central issue in the management of patients with diabetes.  
However a significant practical problem for clinicians is finding a balance between 
control that is adequate to prevent symptoms and reduce the risk for structural 
complications, and the cost of unacceptable side effects including hypoglycemia. This 
risk to benefit ratio is particularly poorly understood in older patients - a heterogeneous 
population with different life expectancies, functionalities, comorbidities, levels of frailty 
(marker of vulnerability which identifies patients with a diminished capacity to 
compensate effectively for external stresses and disability)53 and durations of disease. 6  
Further adding to their treatment complexity is the recent proliferation of 
antihyperglycemic medications that have become available to treat people with diabetes 
in the last decade.  In the older adult population, there has been limited study into the 
efficacy of these medications,10,54 their hypoglycemia risk (Table 2), and their use in this 
vulnerable population. 
1.7 Research aims 
In the current work we aimed to expand our knowledge of antihyperglycemic medication 
prescribing and safety in older adults with diabetes. Our specific aims were to: 
1) Investigate the real-world risk of hypoglycemia for new users of glyburide vs 
modified-release gliclazide (2 sulphonylurea medications). 
2) Investigate patterns in antihyperglycemic medication prescriptions in older adults from 
2002 until 2013, and over the period of study, investigate hospital encounters for 
hypoglycemia.
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Table 2. Real-world studies on the efficacy and safety of antihyperglycemic 
medications  
Authors Study Design Results Conclusions 
Mathieu C 
et al 55 
 
Multicentre prospective 
observational cohort study 
of 45,868 adults with type 
2 diabetes inadequately 
controlled on 1 
antihyperglycemic 
medication.  
Examined treatment 
response and tolerability to 
vildagliptin vs. other oral 
agents (including risk of 
hypoglycemia). 
 
Mean age 57.8± 11.8, 12, 917 
(29.5%) over the age of 65. 
Noted better treatment response and 
tolerability with vildagliptin 
compared with other 
antihyperglycemic medications 
(adjusted odds ratio 1.49 [CI 1.42-
1.55], p<0.001). 
Compared with other 
medications, 
vildagliptin can lower 
HbA1c to target 
without side effects. 
Al-Arouj 
M et al56 
Multicentre prospective 
study from the Middle 
East and Asia of type  2 
patients over the age of 18 
treated with vildagliptin 
(n=684) or sulphonylurea  
(n=631) as add on to 
metformin.  
Primary outcome was the 
proportion with at least 1 
hypoglycemia event 
during the fasting period in 
Ramadan.  
Mean age 49.6 with 10% over the age 
of 65. 
Significantly fewer patients in the 
vildagliptin group experienced a 
hypoglycemia event compared with 
those receiving sulphonylureas (5.4% 
vs 19.8%, p<0.001). 
Vildagliptin was 
associated with 
significantly fewer 
hypoglycemia 
episodes compared 
with sulphonylureas 
and was well-
tolerated in this 
population. 
Freemantle 
N et al 57 
Multicentre, prospective 
cohort study of type 2 
Propensity score matches achieved for 
686 starting premix vs basal insulin, 
Less nocturnal 
hypoglycemia with  
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patients over the age of 40 
who started insulin within 
12 months prior to study 
entry (n= 2374).  
Aimed to examine the 
performance of different 
insulin regimens on 
HbA1c reduction and 
hypoglycemia along with 
body weight change. 
542 starting basal and mealtime vs 
premix, 400 starting basal and 
mealtime (ie bolus).  
Mean age was approximately 60 
across groups. HbA1c reduction did 
not differ between the 3 insulin 
regimens. Relative risk of overall and 
nocturnal hypoglycemia lower 
(p=0.010 to p<0.001) with basal or 
basal plus mealtime compared with 
premix. Similar finding for nocturnal 
(p=0.021) hypoglycemia but not for 
overall hypoglycemia for basal 
compared with basal and mealtime 
regimens. 
basal insulin than 
premix. 
Gitt AK et 
al58 
German prospective cohort 
study of 3810 patients with 
type 2 diabetes over the 
age of 40 on mono or dual 
combination therapy prior 
to study.  
Aimed to examine if DPP-
4 inhibitor compared to 
sulphonylurea provided 
non-inferior glycemic 
control with reductions in 
body weight and lower 
risk of hypoglycemia.  
 
884 received dual therapy with DPP-4 
or sulphonylurea in setting of 
metformin (n=628 and n=256 
respectively). Mean age 64.1 in DPP-
4 group and 67.9 in SU group. 
No significant difference in change in 
HbA1c over the 12 months of 
treatment but hypoglycemia 
significantly less frequent in those 
receiving DPP-4 inhibitors (odds ratio 
0.32  [95% CI 0.19 to 0.54]). 
DPP-4 on top of 
metformin resulted in 
similar HbA1c 
reductions within 12 
months with a 
significant reduction 
in hypoglycemia. 
Holstein et 
al59 
Prospective cohort study 
of  30,768 patients who 
attended the emergency 
room over a 4 year period. 
Glimepiride produced fewer episodes 
of hypoglycemia than glyburide 
(0.86/1000 person-years vs. 5.6/1000 
person years respectively). 
In people with type 2 
diabetes, glimepiride 
associated with fewer 
episodes of severe 
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Aimed to evaluate the 
incidence of severe 
hypoglycemia associated 
with glimepiride and 
glyburide. 
hypoglycemia than 
glyburide in routine 
care. 
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2.1 Introduction 
Sulphonylureas are easy to administer, low in cost, and through their insulin secreting 
mechanism, are amongst the most potent of all oral hypoglycemic agents.1,2 These drugs 
however, must be used very carefully in older adults to avoid hypoglycemia, given that 
this population frequently has medical comorbidities, takes multiple medications, and has 
altered drug metabolism.   
In Canada, glyburide (glibenclamide) and gliclazide are 2 commonly prescribed 
sulphonylureas. Because of glyburide’s high affinity for the sulphonylurea receptor,3 its 
long duration of action, and its glucose lowering metabolites,4 the hypoglycemia risk of 
glyburide is anticipated to be higher than other sulphonylureas.5-7 Accordingly, diabetes 
guidelines have cautioned against the use of glyburide in the elderly in favor of other oral 
hypoglycemic agents.8 However, to our knowledge, the risk of hypoglycemia with 
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glyburide compared with a long-acting alternative, modified-release gliclazide,9 has not 
been examined in a large representative population of older adults in routine practice.  
For this reason we conducted 2 population-based cohort studies to examine the risk of 
hospital encounters with hypoglycemia after the initiation of glyburide vs once-daily 
modified-release gliclazide in the outpatient setting. 
2.2 Methods 
2.2.1 Study design and setting 
We conducted 2 population-based matched retrospective cohort studies of older adults 
using linked health care databases in Ontario, Canada. Ontario has approximately 1.8 
million adults aged 65 years or older who have comprehensive universal healthcare 
including coverage for outpatient prescription medications, physician services, 
hospitalizations and diagnostic testing.10 The reporting of these studies follows guidelines 
for observational studies (Appendix B Table 1).11 
The studies were conducted at the Institute for Clinical Evaluative Sciences (ICES) 
according to a pre-specified protocol which was approved by the research ethics board at 
Sunnybrook Health Sciences Centre (Toronto, Canada). Participant informed consent was 
not required. 
2.2.2 Data sources 
We obtained patient characteristics, drug use, covariate information, and outcome data 
using records from several databases. We ascertained vital statistics from the Registered 
Persons Database of Ontario, which contains demographic information on all Ontario 
residents who have been issued a health card. The Ontario Drug Benefit Program 
database was used to identify prescription drug use and contains accurate records of all 
formulary prescriptions dispensed to those aged 65 years or older, with an error rate of 
less than 1%.12 Diagnostic and procedural information on hospital admissions and 
emergency room visits was abstracted from the Canadian Institute for Health 
Information’s Discharge Abstract Database and the National Ambulatory Care Reporting 
System database, respectively. Covariate information was also derived from the Ontario 
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Health Insurance Plan database, which includes health claims for inpatient and outpatient 
physician services. We used the ICES Physician Database to abstract sulfonylurea 
prescriber information. In previous studies, we have used these databases to research 
adverse drug events and health outcomes.13-18 A subpopulation of patients had laboratory 
creatinine or HbA1c values available in the year prior to the relevant sulphonylurea 
prescription.19,20  
With the exception of sulfonylurea prescriber information (missing in approximately 13% 
of both studies), and income quintile (missing in approximately 0.5% of both studies) the 
databases were complete for all variables used. International Classification of Diseases 
9th Revision (ICD-9) (pre-2002), International Classification of Diseases 10th Revision 
(ICD-10) (post-2002), Canadian Classification of Diagnostic, Therapeutic and Surgical 
Procedures (CCP) (pre-2002) and Canadian Classification of Health Interventions (CCI) 
(post-2002) codes were utilized to assess baseline comorbidities and investigations in the 
5 years prior to the relevant sulphonylurea prescription (Appendix B Table 2). Physician 
visits in the year prior to the sulphonylurea prescription were assessed through provincial 
fee for service codes. Codes used to assess outcomes are detailed in Appendix B Table 3, 
which lists only ICD-10 codes as all events would have occurred after the 
implementation of this coding system in Canada. 
2.2.3 Patients 
To mimic routine practice, we conducted 2 population-based studies of older adults 
newly prescribed glyburide or modified-release gliclazide from April 2002 to December 
2011. In the first study we examined a sulphonylurea prescribed as monotherapy and in 
the second study we examined a sulphonylurea prescribed in the presence of metformin. 
In both studies, the date of the sulphonylurea prescription served as the index date (cohort 
entry date). 
Monotherapy study 
In this study, we excluded the following patients from analysis: 1) those in their first year 
of eligibility for prescription drug coverage (aged 65 years) to avoid incomplete 
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medication records, 2) those who had insulin or any other oral hypoglycemic agent 
dispensed in the year prior to the index date to ensure new oral hypoglycemic agent use, 
3) those who had other medications commonly associated with hypoglycemia (ie. 
pentamidine, quinine, glucagon, indomethacin) dispensed in the year prior to the index 
date,21 4) those with a history of at least one hospital encounter (emergency room or 
hospitalization) with hypoglycemia in the 5 years prior to the index date as antecedent 
hypoglycemia can be associated with hypoglycemic unawareness and recurrent 
episodes,22 5) those with a history of end-stage renal disease in the 5 years prior to the 
index date as reduced renal function may decrease the clearance of  drugs and their 
metabolites, 6) those who were discharged from hospital in the 2 days prior to or on the 
index date to ensure these were new outpatient sulphonylurea prescriptions (because in 
Ontario patients continuing a sulphonylurea initiated in hospital would have their 
medication dispensed on the same day or the day after hospital discharge). A patient 
could only enter the cohort once. Patient selection is presented in Figure 1 of Appendix 
B.  
Metformin combination study 
In this study, in addition to either glyburide or modified-release gliclazide, patients were 
required to have evidence of metformin therapy (dispensed on the index date or 
dispensed at least once in the 180 days prior to the index date with the day supply 
covering the index date). The exclusion criteria applied were as in the monotherapy 
study, with the exception of excluding patients with oral hypoglycemic agents other than 
metformin dispensed in the year prior to the index date (Appendix B Figure 2). 
In each study, we restricted the analysis to comparable sulphonlyurea dosages - glyburide 
total doses of 5, 10, 15, and 20 mg per day, and modified release gliclazide total doses of 
30, 60, 90 and 120 mg per day.   
2.2.4 Outcomes 
In both studies, outcomes were assessed 90 days after the index date for the primary 
analysis. We chose 90 days of follow-up to avoid crossover in drug therapy that could 
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occur with longer periods of follow up, and because prescriptions covered by Ontario’s 
drug plan are prescribed at no more than 100-day intervals. 
The primary outcome was a hospital encounter (emergency room visit or hospital 
admission) with hypoglycemia. The secondary outcome was all-cause mortality (any 
death in or outside of hospital). The validity of the diagnostic codes used to identify these 
outcomes is presented in Table 3 of Appendix B. 
2.2.5 Statistical analysis 
We used similar statistical methods in each of the 2 studies. Baseline characteristics were 
compared between glyburide and gliclazide users using standardized differences. This 
metric describes differences between group means relative to the pooled standard 
deviation and is considered a meaningful difference if greater than 10%.23  
A propensity score for the potential receipt of gliclazide was derived from a logistic 
regression model where treatment status was regressed on a set of 19 and 21 baseline 
covariates in each study respectively.24 Covariates were selected on the basis of their 
potential association with oral hypoglycemic agent use or the study outcome, and 
included comorbidities, medications, health care visits, investigations and laboratory 
testing. We then retained each glyburide user who could be matched with a gliclazide 
user (1:1 match). Groups were matched using a nearest neighbor “greedy” matching 
algorithm on the basis of the logit of their propensity score (with a caliper width of ± 0.6 
standard deviations),24 age (±2 years), the presence of chronic kidney disease, at least one 
endocrinologist visit in the year prior, and the prescribed equivalent dose of glyburide or 
gliclazide (5 mg of glyburide equivalent to 30 mg of modified release gliclazide).9,25-28 
Matching on characteristics apart from the propensity score was completed in order to 
ensure good balance on prognostically important characteristics,24 and to facilitate 
potential subgroup analyses. We then assessed the degree of balance in measured 
covariates between groups by examining post-match standardized differences which were 
less than 10% for over 55 characteristics in both studies.  
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The referent group consisted of older adults who were prescribed gliclazide. We 
estimated absolute risk differences by directly examining the percentage of patients in 
each treatment group with an encounter for hypoglycemia within 90 days. Absolute risk 
was also expressed as the number needed to harm (NNH) which is the reciprocal of the 
risk difference (1 / absolute risk difference). To account for matching, we used 
conditional logistic regression to estimate unadjusted odds ratios (OR) and 95% 
confidence intervals (CI’s). OR’s can be interpreted as relative risks (RR) (appropriate 
given the incidences observed).   
To assess the robustness of our primary outcome, we also carried out several additional 
secondary analyses. These analyses were carried out after knowledge of our primary 
results. First, we adjusted our conditional OR’s for the year of study cohort entry.  
Further, we extended follow-up beyond 90 days, terminating the observation period for 
reasons of death, study sulphonylurea discontinuation, receipt of a non-study 
hypoglycemic agent, or the last date of available records (March 31, 2012) and used Cox 
regression analyses stratified on matched sets.   
Additionally, we performed other analyses to put the results into context and to guide the 
types of physicians to target with educational initiatives. We examined the total 90-day 
cost of all prescription drugs to the provincial health care program in glyburide vs. 
gliclazide users and tested for a statistical difference between the cost distributions using 
a Kruskal-Wallis test. We also examined physician characteristics associated with 
glyburide (versus gliclazide) prescriptions in the last 3 years of study accrual using 
conditional logistic regression [covariates included year since medical school graduation, 
physician sex, and practicing in a rural setting (population less than 10,000)]. 
We conducted all analyses with SAS version 9.3 (SAS Institute, Cary, North Carolina). 
We interpreted 2-tailed p values lower than 0.05 as statistically significant. 
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2.3 Results 
2.3.1 Monotherapy study baseline characteristics 
We identified 18,804 patients prescribed glyburide (n = 13,550) or gliclazide (n = 5254). 
Baseline characteristics of the 2 groups before and after matching are presented in Table 
3, and the characteristics of patients with and without laboratory values available in the 
year prior are illustrated in Appendix B Table 4. After matching, we retained 4374 
patients in each group, and baseline characteristics were similar between the groups.  
Over the course of the study, there were 4288 unique health care prescribers of glyburide 
or gliclazide and approximately 78% of prescribers were primary care physicians.  
Prescriptions were filled across 464 pharmacies. Over the years of accrual, glyburide 
continued to be initiated in routine care. However, there was a trend to fewer initiations 
over time with 609 prescriptions in 2002 (34 per 100,000 older adults in the general 
population) and 132 prescriptions in 2011 (7 per 100,000 older adults).  The initiation of 
gliclazide increased from 6 in 2002 (at a time when the medication was not covered 
under Ontario’s universal prescription drug plan) to 839 prescriptions in 2011 (47 per 
100,000 older adults).   
2.3.2 Monotherapy study outcomes 
Prescribing glyburide was associated with a higher risk of a hospital encounter with 
hypoglycemia compared with gliclazide (69 patients of 4374 taking glyburide [1.60%] vs 
8 patients of 4374 taking gliclazide [0.18%], absolute risk increase 1.40% [95% CI 
1.01% to 1.79%], OR 8.63 [95% CI 4.15 to 17.93], p < 0.0001). Prescribing glyburide 
was not associated with a significantly higher risk of all-cause mortality compared with 
gliclazide (100 patients of 4374 taking glyburide [2.29%] vs 84 patients of 4374 taking 
gliclazide [1.92%], absolute risk increase 0.37% [95% CI -0.21% to 0.95%], OR 1.21 
[95% CI 0.89 to 1.63], p=0.22) (Table 4). 
2.3.3 Metformin combination study baseline characteristics 
We identified 26,598 patients prescribed glyburide (n= 16,631) or gliclazide (n= 9967) in 
the presence of metformin. Baseline characteristics of the 2 groups before and after 
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matching are presented in Table 5, and the characteristics of those with and without 
laboratory values available in the year prior are illustrated in Appendix B Table 4. After 
matching, we retained 8038 patients in each group, and baseline characteristics were 
similar between groups. Metformin continued to be used in follow-up in both groups, 
with evidence of repeat prescriptions after the index date in 6403 of 8038 (80%) 
glyburide users and 6660 of 8038 (83%) gliclazide users (standardized difference 8%). 
Over the course of the study, there were 7913 unique health care prescribers of glyburide 
or gliclazide and about 78% of prescribers were primary care physicians. Prescriptions 
were filled across 477 pharmacies. Over the years of accrual, glyburide continued to be 
initiated in routine care. There were 411 prescriptions in 2002 (23 per 100,000 older 
adults in the general population) and 376 prescriptions in 2011 (21 per 100,000). The 
initiation of gliclazide increased from less than 5 prescriptions in 2002 (at a time when 
the medication was not covered under the universal prescription drug plan) to 1905 
prescriptions in 2011 (106 per 100,000). 
2.3.4 Metformin combination study outcomes 
Prescribing glyburide was associated with a higher risk of a hospital encounter with 
hypoglycemia compared with prescribing gliclazide (110 patients of 8038 taking 
glyburide [1.37%] vs 19 patients of 8038 taking gliclazide [0.24%], absolute risk increase 
1.13% [95% CI 0.86% to 1.40%], OR 6.06 [95% CI 3.68 to 9.97], p<0.0001). Prescribing 
glyburide was also associated with a higher risk of all-cause mortality compared with 
gliclazide (109 patients of 8038 taking glyburide [1.36%] vs 75 patients of 8038 taking 
gliclazide [0.9%], absolute risk increase 0.43% [95% CI 0.10% to 0.76%], OR 1.47 [95% 
CI 1.09 to 1.97], p=0.012) (Table 5). 
2.3.5 Additional analyses 
The primary outcome associations in each study proved robust in additional analyses. 
Prescribing glyburide remained associated with a 90-day higher risk of a hospital 
encounter with hypoglycemia compared with prescribing gliclazide after adjustment for 
the year of cohort entry (monotherapy study adjusted OR 4.47 [95% CI 1.66 to 12.05], 
p=0.003; metformin combination study adjusted OR 5.90 [95% CI 2.85 to 12.18], 
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p<0.0001). Additionally, in time to event analyses, prescribing glyburide remained 
associated with a higher risk of a hospital encounter with hypoglycemia (monotherapy 
study HR 6.71 [95% CI 3.04 to 14.85], p<0.0001); metformin combination study HR 
5.78 [95% CI 3.50 to 9.52], p<0.0001) (Appendix B Table 5 and 6). 
In further analyses, encounters with hypoglycemia decreased throughout the study period 
from 1.5% in 2002 to less than 0.5% in 2011.  Encounters took place across 77 different 
emergency rooms or hospitals. In the emergency room setting, day time visits (between 
hours of 8AM and 8PM) were more frequent than night time visits (between hours of 
8PM and 8AM) (39 vs 24 visits, respectively). Similar findings were observed in the 
metformin combination study (99 different emergency rooms or hospitals, 68 day time vs 
31 night time visits). When we examined total 90-day prescription costs to the provincial 
drug program (in 2012 Canadian dollars), in both studies the median per patient 90-day 
cost of drugs for glyburide patients was slightly less than gliclazide patients 
(monotherapy study $474 vs $525, p=0.006; metformin combination study $499 vs $528, 
p=0.017).  Finally, when we examined the characteristics of physicians who prescribed 
glyburide (vs. gliclazide), in both studies the year since medical school graduation, 
physician sex, and practicing in a rural setting were not associated with prescribing 
glyburide. In the monotherapy study, being a foreign (vs Canadian) trained physician was 
associated with a higher likelihood of prescribing glyburide (adjusted OR 1.38 [95% CI 
1.03 to 1.83]), an association not observed in the metformin combination study (adjusted 
OR 1.01 [95% CI 0.87 to 1.18]). 
2.4 Discussion 
2.4.1 Principal findings and main implications 
Despite cautionary guidelines, glyburide still continues to be initiated in older adults in 
routine care.8 Yet, long-acting modified-release gliclazide is more convenient for patients 
to take (once a day) than many glyburide dosing regimens. When prescribed as 
monotherapy or in the presence of metformin, modified-release gliclazide is a safer 
sulfonylurea than glyburide and is associated with less hypoglycemia. Although 
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modified-release gliclazide has a long duration of action, its hypoglycemia risk might be 
lower as it has no known active drug metabolites.27,29  
At the population level, it is possible that many hospital encounters and even some deaths 
may be prevented by avoiding glyburide in favor of modified-release gliclazide. 
Prescription costs for glyburide and gliclazide patients were similar, and avoiding the 
former could also reduce associated health care costs of hypoglycemia management. 
2.4.2 Results in relation to other studies 
Patients studied in randomized controlled trials typically have more regimented treatment 
and monitoring than those studied in routine practice and may not include vulnerable 
patient groups. In this way the findings from our population-based study extend the 
results of randomized controlled trials, where the increase in risk was greater than 
previous trials. In a systematic review and meta-analysis of randomized controlled trials, 
glyburide was associated with a 44% greater risk (RR 1.44 [95% CI 1.13 to 1.85]) of 
hypoglycemic episodes compared with other sulphonylureas (including immediate 
release gliclazide, glimepiride, and chlorpropamide) across 2 studies (n=1365).30 Where 
studies (n=1365) examined the risk of severe hypoglycemic events (ie. events requiring 
assistance or a hospital presentation), there was no significant difference between those 
prescribed glyburide vs other sulphonlyureas (RR 4.69 [95% CI 0.78 to 28.08]). In 
contrast, in our population-based study the relative risk of a hospital encounter with 
hypoglycemia was over 500% greater with glyburide compared with modified release 
gliclazide. 
Our results also extend the findings of a prior population-based study examining rates of 
hypoglycemia in adult sulphonylurea users, published over 10 years ago. When glyburide 
was compared with immediate release gliclazide (recognizing modified-release gliclazide 
was the comparator in our study), glyburide users had a higher risk of hypoglycemia, as 
assessed from the medical records of general practitioners (adjusted RR 1.35 [95% CI 
1.09 to 1.69]).31  
33 
 
In our metformin-glyburide combination study we also noted that glyburide vs gliclazide 
was associated with a higher risk of all-cause mortality. Sulfonylurea induced 
hypoglycemia has been reported to have a case-fatality rate of 4-10%.32 However, the 
increased mortality in the metformin-glyburide group could have been the result of 
unmeasured or incompletely quantified confounding variables.33 
2.4.3 Strengths and limitations 
To our knowledge our studies are the first to quantify the risk of hypoglycemia after 
initiating glyburide compared with modified-release gliclazide in older adults in a real 
practice setting. Compared with an older population-based study of sulphonylurea users 
(noted above),31 we accounted for a number of baseline comorbidities, medications, and 
measures of health care utilization including physician visits, investigations and 
laboratory testing. We also excluded those on concomitant hypoglycemic agents to help 
reduce confounding (apart from metformin in our combination study).  Additionally, we 
matched patients based on the dose equivalence of their prescription. Where a previous 
study included self-reported hypoglycemia,31 in our studies, hypoglycemia was 
documented in hospital records by the treating health care team.  
To raise awareness, target education and quality assurance, we also illustrated trends in 
glyburide use, characterized hypoglycemia encounters, explored the costs of 
prescriptions, and examined the characteristics of recent glyburide prescribers. Our 
research protocols, cohorts and outcomes were also prespecified, and the results were 
consistent with our a priori hypotheses. Additional strengths of our 2 studies include our 
examination of hypoglycemic episodes leading to hospital presentation, a more extreme 
outcome in the spectrum of hypoglycemia. Such an outcome may help convince 
clinicians, pharmacists and policy makers about the importance of this safety concern.  
Our studies do have some limitations. Prospective data collection with independent 
outcome adjudication is a preferred methodology to a retrospective database study. Also, 
we assessed the outcome of a hospital encounter with hypoglycemia with administrative 
codes which have limited sensitivity and accuracy compared to laboratory plasma 
glucose measurements (although the latter is not the best reference standard as treatment 
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with glucose has frequently been initiated in many hypoglycemic episodes by the time 
plasma glucose is measured). Although episodes of hypoglycemia may be 
underrepresented in our studies, we had no reason to believe they were assessed 
differently in those prescribed glyburide vs gliclazide. We were also only able to 
accurately ascertain medications dispensed with no information on medication use. 
Additionally we were unable to capture hypoglycemic episodes experienced outside of 
hospital. Further, our cost analysis was a simple calculation of the 90-day cost of all 
medications to the Ontario government and we did not carry out more detailed economic 
analyses. 
Residual confounding is an additional consideration in all observational studies, and in 
the current studies we had no information on factors such as nutrition, glucose monitoring 
and patient education which may have influenced the association between sulphonylurea 
type and outcome. However, using a matching technique we did obtain good balance on a 
large number of measured baseline characteristics between the two groups. As well, the 
magnitude of the relative risk of hypoglycemia was large in both studies and our results 
proved robust in additional statistical analyses, making it unlikely that the association can 
be explained entirely by confounding factors. 
2.4.4 Conclusions 
Although glyburide is effective in lowering blood glucose in patients with diabetes, its 
use in older adults is associated with a much higher risk of hypoglycemia than modified-
release gliclazide. The results of our studies may help convince physicians, pharmacists 
and patients who still use glyburide to consider modified-release gliclazide as a more 
convenient and safer alternative. 
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Table 3: Key Baseline characteristics of the monotherapy study 
 
Unmatched Matched 
 
 
Glyburide 
n=13,550 
Gliclazide  
n=5254 
Standardized 
Difference a 
Glyburide 
n=4374 
Gliclazide  
n=4374 
Standardize
d Difference 
a
 Demographics 
Age, Years* 74.52 76.10 23% 75.66 75.66 0% 
Female* 6414 (47.34) 2596 (49.41) 4% 2138 (48.88) 2138 (48.88) 0% 
Income based socioeconomic status b 
Quintile 1 (lowest) 3189 (23.54) 1085 (20.65) 7% 994 (22.73) 881 (20.14) 6% 
Rural Location 1654 (12.21) 635 (12.09) 0% 484 (11.07) 542 (12.39) 4% 
Year of cohort entry c 
2002  2432 (17.95) 6 (0.11) 65% 609 (13.92) 6 (0.14) 56% 
2003 2640 (19.48) 18 (0.34) 68% 724 (16.55) 18 (0.41) 61% 
2004 2115 (15.61) 16 (0.30) 59% 643 (14.70) 16 (0.37) 56% 
2005 1754 (12.94) 23 (0.44) 52% 569 (13.01) 21 (0.48) 52% 
2006 1507 (11.12) 24 (0.46) 47% 551 (12.60) 23 (0.53) 50% 
2007 1061 (7.83) 996 (18.96) 33% 423 (9.67) 852 (19.48) 28% 
2008 731 (5.39) 821 (15.63) 34% 309 (7.06) 696 (15.91) 28% 
2009 574 (4.24) 1168 (22.23) 55% 251 (5.74) 968 (22.13) 49% 
2010 419 (3.09) 1163 (22.14) 60% 163 (3.73) 935 (21.38) 55% 
2011 317 (2.34) 1019(19.39) 57% 132 (3.02) 839 (19.18) 53% 
Long term care  443 (3.27) 239 (4.55) 7% 165 (3.77) 197 (4.50) 4% 
Charlson Comorbidity Index d  
0 or no hospitalizations 8967 (66.18) 3088 (58.77) 15% 2648 (60.54) 2665 (60.93) 1% 
1 1585 (11.70) 743 (14.14) 7% 576 (13.17) 589 (13.47) 1% 
2 1344 (9.92) 594 (11.31) 5% 501 (11.45) 481 (11.00) 1% 
≥3  1654 (12.21) 829 (15.78) 10% 649 (14.84) 639 (14.61) 1% 
Health care visits in the prior year 
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Cardiologist visit * 4476 (33.03) 2181 (41.51) 18% 1724 (39.41) 1739 (39.76) 1% 
Ophthalmologist visit  3614 (26.67) 1588 (30.22) 8% 1331 (30.43) 1275 (29.15) 3% 
Endocrinologist visit*  767 (5.66) 465 (8.85) 12% 363 (8.30) 363 (8.30) 0% 
Internist visit  2936 (21.67) 1414 (26.91) 12% 1101 (25.17) 1150 (26.29) 3% 
Sulphonylurea prescriber 
General practitioner 10,393 (76.70) 4152 (79.03) 6% 3398 (77.69) 3474 (79.42) 4% 
Internist  208 (1.54) 144 (2.74) 8% 78 (1.78) 119 (2.72) 8% 
Endocrinologist  149 (1.10) 161 (3.06) 14% 66 (1.51) 118 (2.70) 8% 
Other 836 (6.17) 259 (4.93) 5% 272 (6.22) 221 (5.05) 5% 
Missing 1961 (14.47) 535 (10.18) 13% 560 (12.80) 439 (10.04) 9% 
Comorbidities e 
Chronic kidney disease* f 1010 (7.45) 886 (16.86) 29% 601 (13.74) 601 (13.74) 0% 
Congestive heart failure* 2055 (15.17) 969 (18.44) 9% 722 (16.51) 758 (17.33) 2% 
Thyroid disease g 1118 (8.25) 514 (9.78) 5% 431 (9.85) 420 (9.60) 1% 
Investigations h 
Carotid ultrasound 1638 (12.09) 804 (15.30) 9% 655 (14.97) 650 (14.86) 0% 
Coronary angiogram 885 (6.53) 498 (9.48) 11% 371 (8.48) 403 (9.21) 3% 
Coronary revascularization 537 (3.96) 262 (4.99) 5% 240 (5.49) 210 (4.80) 3% 
Echocardiography* 4379 (32.32) 2334 (44.42) 25% 1853 (42.36) 1851 (42.32) 0% 
Holter monitoring* 1744 (12.87) 1025 (19.51) 18% 772 (17.65) 805 (18.40) 2% 
Stress test  3753 (27.70) 1845 (35.12) 16% 1506 (34.43) 1491 (34.09) 1% 
At least one HbA1c test* 10208 (75.34) 4738 (90.18) 40% 3895 (89.05) 3876 (88.61) 1% 
Diabetes management * i 629 (4.64) 1122 (21.36) 51% 485 (11.09) 582 (13.31) 7% 
Diabetes incentive* j 413 (3.05) 1028 (19.57) 54% 336 (7.68) 455 (10.40) 9% 
Medications k 
ACE inhibitors 4287 (31.64) 1813 (34.51) 6% 1551 (35.46) 1503 (34.36) 2% 
ARBs* 1482 (10.94) 1281 (24.38) 36% 891 (20.37) 904 (20.67) 1% 
Antidepressants* 1466 (10.82) 815 (15.51) 14% 612 (13.99) 629 (14.38) 1% 
Beta blockers 3428 (25.30) 1733 (32.98) 17% 1341 (30.66) 1346 (30.77) 0% 
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                Data presented as number (percent) except where indicated. 
Cell sizes less than six were not reported for reasons of privacy. 
Abbreviations: ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, HbA1c glycosylated hemoglobin, IQR interquartile range, GFR glomerular 
filtration rate, SD standard deviation. 
Variables marked * were included as covariates in the propensity score model. 
Corticosteroids* 2575 (19.00) 1000 (19.03) 0% 794 (18.15) 823 (18.82) 2% 
Ezetimibe* 131 (0.97) 280 (5.33) 25% 100 (2.29) 122 (2.79) 3% 
Glucose test strips* 20 (0.15) 164 (3.12) 24% 16 (0.37) 20 (0.46) 1% 
H2 Receptor Antagonists* 1083 (7.99) 219 (4.17) 16% 207 (4.73) 238 (5.44) 3% 
Loop diuretics 1790 (13.21) 913 (17.38) 12% 686 (15.68) 688 (15.73) 0% 
Potassium sparing 
diuretics 
867 (6.40) 350 (6.66) 1% 299 (6.84) 279 (6.38) 2% 
Statins* 4155 (30.66) 2730 (51.96) 44% 2044 (46.73) 2094 (47.87) 2% 
Thiazide diuretics 2040 (15.06) 939 (17.87) 8% 747 (17.08) 742 (16.96) 0% 
Thyroid replacement* 1291 (9.53) 763 (14.52) 15% 553 (12.64) 582 (13.31) 2% 
Drug Dosage l 
1 8496 (62.70) 3905 (74.32) 25% 3246 (74.21) 3246 (74.21) 0% 
2 3649 (26.93) 982 (18.69) 20% 899 (20.55) 899 (20.55) 0% 
3 343 (2.53) 123 (2.34) 1% 96 (2.19) 96 (2.19) 0% 
4 857 (6.32) 152 (2.89) 16% 133 (3.04) 133 (3.04) 0% 
Laboratory Data m 
Evidence of creatinine 
value 
2505 (18.49) 1373 (26.13) 18% 896 (20.48) 1108 (25.33) 12% 
Mean creatinine (umol/L) 
(SD) 
93.25 (38.55) 103.89 (47.14) 25% 97.54 (40.74) 100.71 (46.81) 7% 
Median creatinine 
(umol/L) (IQR) 
83.71 (69.32-
105.76) 
93.29 (74.12-123.02) --- 85.81 (72.20-
111.51) 
90.42 (72.20-
117.13) 
--- 
Mean GFR (mL/min/1.73 
m2) (SD) 
67.78 (19.82) 60.33 (21.72) 36% 64.75 (20.49) 62.29 (20.61) 12% 
Median GFR 
(mL/min/1.73 m2) (IQR) 
70.83 (54.49-
83.91) 
60.47 (43.86-78.40) --- 67.27 (48.85-
82.04) 
63.21 (46.46-
80.61) 
--- 
Evidence of HbA1c value 1639 (12.10) 1096 (20.86) 24% 641 (14.65) 877 (20.05) 14% 
Mean HbA1c  (SD) 0.079 (0.019) 0.075 (0.015) 22% 0.077 (0.018) 0.075 (0.015) 15% 
Median HbA1c (IQR) 0.074 (0.066-
0.086) 
0.072 (0.066-0.080) --- 0.073 (0.066-
0.083) 
0.072 (0.065-
0.080) 
--- 
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a
 Standardized differences are less sensitive to sample size than traditional hypothesis tests.  They provide a measure of the difference between groups divided by the 
pooled standard deviation; a value greater than 10% (0.1) is interpreted as a meaningful difference between the groups. 
b
 Income was categorized into fifths of average neighborhood income on the index date. 
c
 The year of cohort entry is also referred to as the index date. 
d
 Charlson Comorbidity Index was calculated using five years of hospitalization data. “No hospitalizations” received a score of 0. 34 
e
 Comorbidities were assessed by administrative database codes in the previous five years. 
Less than 5% had evidence of a nephrologist visit in the one year prior or evidence of alcoholism, chronic liver disease, peripheral vascular disease, sepsis or pancreatitis 
in the five years prior. Less than 1% had evidence of pituitary disease, adrenal disease, pancreatic cancer or diabetic retinopathy in the five years prior. 
f We identified individuals with chronic kidney disease using a validated algorithm of diagnosis and physician claim codes.  In Ontario, this algorithm identifies patients 
with a median estimated glomerular filtration rate (eGFR) of 38 mL/min per 1.73 m2 (interquartile range 27 to 52).  Its absence identifies patients with a median eGFR of 
69 mL/min per 1.73 m2 (interquartile range 56 to 82). 35 
g
 Thyroid disease includes hypothyroidism, thyroiditis, iodine deficiency related thyroid disorders, nontoxic goiter, thyrotoxicosis, and other disorders of the thyroid. 
h
 Investigations were assessed by administrative codes in the previous five years. 
i
 Diabetes management is an all-inclusive service payable to the most responsible physician for providing continuing management and support of a diabetic patient. The 
service must include assessments focusing on diabetic target organ systems, relevant counseling and maintenance of a diabetic flow sheet retained on the patient’s 
permanent medical record. The flow sheet must track lipids, cholesterol, HbA1C, urinalysis, blood pressure, fundal examination, peripheral vascular examination, 
weight, body mass index and medication dosage. 36  
j
 Diabetes management incentive is a fee rendered to a general practitioner providing ongoing management of a diabetic patient consistent with the requirements of the 
Canadian Diabetes Association including a minimum of lipid, HbA1C, blood pressure, body mass index measurement, albumin:creatinine, preventative measures and 
health promotion, referral for dilated eye exam, foot and neurological exam over the previous 12 months.36  
k Baseline medication use was assessed in the previous 120 days.  
Less than 5% received prescriptions for atypical antipsychotics, amiodarone, clarithromycin, fibrates, gatifloxacin or sulphonamides. Less than 1% received prescriptions 
for valproic acid, protease inhibitors, monoamine oxidase inhibitors, danazol, isoniazid, disopyramine, tacrolimus/sirolimus, probenicid, rifampin, aliskerin, androgens, 
barbiturates, carbamazepine, clonidine, cyclosporine, fluconazole/voriconazole, tetracycline. There were no prescriptions for acetohexamide, chloramphenicol, 
pegvisimont, colesevelam, reserpine, guanethidine, ifosfamide, phenylbutazone, diazoxide, aprepitant and bosentan.  
l Drug dose level 1=glyburide 5mg/modified release gliclazide 30mg, 2=glyburide 10mg/ modified release gliclazide 60mg, 3=glyburide 15mg/ modified release 
gliclazide 90 mg,  4=glyburide 20mg/modified release gliclazide 120 mg. 
m Where available, laboratory data was collected in the one year previous. 
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Table 4: Key baseline characteristics the metformin combination study 
 
 Unmatched Matched 
 Glyburide 
n=16,631 
Gliclazide 
n=9967 
Standardized 
Difference a 
Glyburide 
n=8038 
Gliclazide 
n=8038 
Standardized 
Difference a 
Demographics 
Age, years* 73.12 73.58 8% 73.34 73.33                0% 
Female* 7952 (47.81) 4572 (45.87) 4% 3707 (46.12) 3707 (46.12) 0% 
Income based socioeconomic status b 
Quintile 1 (lowest) 3931 (23.64) 2080 (20.87) 7% 1793 (22.31) 1715 (21.34) 2% 
Rural location 2036 (12.24) 1247 (12.51) 1% 1031 (12.83) 997 (12.40) 1% 
Year of cohort entry c 
2002 1191 (7.16) <=5 (0.05) 39% 411 (5.11) <=5 (<=0.06) -- 
2003 1910 (11.48) 8 (0.08) 50% 743 (9.24) 7 (0.09) 44% 
2004 2202 (13.24) 15 (0.15) 54% 930 (11.57) 14 (0.17) 50% 
2005 2280 (13.71) 18 (0.18) 55% 1050 (13.06) 18 (0.22) 53% 
2006 2585 (15.54) 34 (0.34) 59% 1306 (16.25) 29 (0.36) 60% 
2007 2070 (12.45) 1013 (10.16) 7% 1137 (14.15) 873 (10.86) 10% 
2008 1460 (8.78) 1386 (13.91) 16% 777 (9.67) 1161 (14.44) 15% 
2009 1218 (7.32) 2163 (21.70) 42% 722 (8.98) 1754 (21.82) 36% 
2010 1036 (6.23) 2904 (29.14) 63% 586 (7.29) 2275 (28.30) 57% 
2011 679 (4.08) 2424 (24.32) 61% 376 (4.68) 1905 (23.70) 57% 
Long term care  268 (1.61) 173 (1.74) 1% 120 (1.49) 144 (1.79) 2% 
Charlson Comorbidity Index d 
0 or no hospitalizations 11,164 
(67.13) 
5857 (58.76) 17% 5146 (64.02) 4902 (60.99) 6% 
1 2150 (12.93) 1682 (16.88) 11% 1137 (14.15) 1281 (15.94) 5% 
2 1575 (9.47) 1063 (10.67) 4% 844 (10.50) 808 (10.05) 1% 
≥3 1742 (10.47) 1365 (13.70) 10% 911 (11.33) 1047 (13.03) 5% 
Health care visits in the year prior 
Cardiologist visit * 5397 (32.45) 3685 (36.97) 10% 2849 (35.44) 2900 (36.08) 1% 
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Ophthalmologist visit  4469 (26.87) 2956 (29.66) 6% 2392 (29.76) 2298 (28.59) 3% 
Endocrinologist visit * 1072 (6.45) 884 (8.87) 9% 696 (8.66) 696 (8.66) 0% 
Internist visit * 3440 (20.68) 2564 (25.72) 12% 1972 (24.53) 1992 (24.78) 1% 
Sulphonylurea prescriber 
General practitioner 12,894 
(77.53) 
7862 (78.88) 3% 6248 (77.73) 6343 (78.91) 3% 
Endocrinologist  353 (2.12) 398 (3.99) 11% 181 (2.25) 294 (3.66) 8% 
Internist  296 (1.78) 296 (2.97) 8% 154 (1.92) 244 (3.04) 7% 
Other 771 (4.64) 384 (3.85) 4% 344 (4.28) 318 (3.96) 2% 
Missing 2347 (14.11) 1024 (10.28) 12% 1111 (13.82) 837 (10.41) 10% 
Comorbidities e 
Chronic kidney 
disease* f 
723 (4.35) 640 (6.42) 9% 420 (5.23) 420 (5.23) 0% 
Congestive heart 
failure* 
1805 (10.85) 1026 (10.29) 2% 813 (10.11) 810 (10.08) 0% 
Thyroid disease g 1193 (7.17) 711 (7.13) 0% 610 (7.59) 557 (6.93) 3% 
Investigations h 
Carotid ultrasound 1924 (11.57) 1433 (14.38) 8% 1072 (13.34) 1114 (13.86) 2% 
Coronary angiogram 1247 (7.50) 935 (9.38) 7% 763 (9.49) 714 (8.88) 2% 
Coronary 
revascularization 
737 (4.43) 540 (5.42) 5% 458 (5.70) 400 (4.98) 3% 
Echocardiography* 5368 (32.28) 4150 (41.64) 19% 3172 (39.46) 3182 (39.59) 0% 
Holter monitoring* 2063 (12.40) 1611 (16.16) 11% 1214 (15.10) 1238 (15.40) 1% 
Stress test  4943 (29.72) 3625 (36.37) 14% 2832 (35.23) 2805 (34.90) 1% 
At least 1 HbA1c test * 14431 
(86.77) 
9317 (93.48) 23% 7474 (92.98) 7416 (92.62) 3% 
Diabetes management 
* 
i
 
2023 (12.16) 3275 (32.86) 51% 1698 (21.12) 1905 (23.70) 6% 
Diabetes incentive* j 1382 (8.30) 2952 (29.60) 60% 1245 (15.49) 1496 (18.61) 8% 
Medications k 
ACE inhibitors 6403 (38.50) 4085 (40.99) 5% 3464 (43.10) 3225 (40.12) 6% 
ARBs* 2644 (15.90) 2641 (26.50) 26% 1854 (23.07) 1876 (23.34) 1% 
Antidepressants* 1778 (10.69) 1289 (12.93) 7% 971 (12.08) 1002 (12.47) 1% 
Beta blockers 4166 (25.05) 2951 (29.61) 10% 2405 (29.92) 2244 (27.92) 4% 
Corticosteroids* 2583 (15.53) 1582 (15.87) 1% 1264 (15.73) 1272 (15.82) 0% 
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Clonidine 38 (0.23) 20 (0.20) 1% 22 (0.27) 14 (0.17) 2% 
Ezetimibe* 243 (1.46) 563 (5.65) 23% 218 (2.71) 266 (3.31) 3% 
Glucose test strips* 78 (0.47) 223 (2.24) 15% 74 (0.92) 99 (1.23) 3% 
H2 receptor blockers* 992 (5.96) 357 (3.58) 11% 318 (3.96) 355 (4.42) 2% 
Loop diuretics 1486 (8.94) 885 (8.88) 0% 745 (9.27) 677 (8.42) 3% 
Potassium sparing 
diuretics 
734 (4.41) 414 (4.15) 1% 362 (4.50) 318 (3.96) 3% 
Statins* 7089 (42.63) 6112 (61.32) 38% 4635 (57.66) 4589 (57.09) 1% 
Thiazide diuretics* 2865 (17.23) 1868 (18.74) 4% 1484 (18.46) 1473 (18.33) 0% 
Thyroid replacement* 1597 (9.60) 1154 (11.58) 6% 866 (10.77) 866 (10.77) 0% 
Drug Dosage l 
1 8430 (50.69) 7212 (72.36) 46% 5620 (69.92) 5620 (69.92) 0% 
2 5707 (34.32) 2038 (20.45) 31% 1908 (23.74) 1908 (23.74) 0% 
3 459 (2.76) 217 (2.18) 4% 169 (2.10) 169 (2.10) 0% 
4 1895 (11.39) 377 (3.78) 29% 341 (4.24) 341 (4.24) 0% 
Laboratory Data m       
Serum creatinine value 
available 
3645 (21.92) 2688 (26.97) 12% 1954 (24.31) 2138 (26.60) 5% 
Mean creatinine 
(umol/L) (SD) 
84.83 (27.58) 87.22 (30.53) 8% 85.34 (27.31) 86.57 (29.74) 4% 
Median creatinine 
(umol/L) (IQR) 
79.87 (67.41-
95.21) 
81.79 (68.37-97.13) --- 79.87 (67.41-
95.21) 
80.83 (68.00-
96.17) 
--- 
Mean GFR 
(mL/min/1.73 m2) 
72.23 (17.73) 70.99 (18.48) 7% 71.87 (17.71) 71.53 (18.37) 2% 
Median (mL/min/1.73 
m2) (IQR) 
74.93 (60.41-
86.96) 
74.08 (59.13-86.19) --- 74.13 (59.85-
86.78) 
74.92 (59.91-
86.43) 
--- 
HbA1c value available 3333 (20.04) 2484 (24.92) 12% 1836 (22.84) 1960 (24.38) 4% 
Mean HbA1c (SD) 0.083 (0.020) 0.080 (0.018) 14% 0.081 (0.018) 0.081 (0.019) 2% 
Median HbA1c (IQR) 0.078 (0.070-
0.092) 
0.076 (0.070-0.085)  0.076 (0.069-
0.087) 
0.076 (0.070-
0.087) 
 
Data presented as number (percent) except where indicated.    
Cell sizes less than 6 were not reported for reasons of privacy. 
Abbreviations: ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, HbA1c glycosylated hemoglobin, IQR interquartile range, GFR glomerular filtration rate, 
SD standard deviation. 
Variables marked * were included as covariates in the propensity score. 
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a Standardized differences are less sensitive to sample size than traditional hypothesis tests.  They provide a measure of the difference between groups divided by the pooled standard 
deviation; a value greater than 10% (0.1) is interpreted as a meaningful difference between the groups. 
b Income was categorized into fifths of average neighborhood income on the index date. 
c The year of cohort entry is also referred to as the index date. 
d Charlson Comorbidity Index was calculated using five years of hospitalization data. “No hospitalizations” received a score of 0. 34 
e Comorbidities were assessed by administrative database codes in the previous five years. 
Less than 5% had evidence of a nephrologist visit in the one year prior or evidence of chronic liver disease, peripheral vascular disease or sepsis in the five years prior. Less than 1% 
had evidence of alcoholism, diabetic retinopathy, pituitary disease, adrenal disease, pancreatitis, pancreatectomy or pancreatic cancer in the five years prior. 
f We identified individuals with chronic kidney disease using a validated algorithm of diagnosis and physician claim codes.  In Ontario, this algorithm identifies patients with a 
median estimated glomerular filtration rate (eGFR) of 38 mL/min per 1.73 m2 (interquartile range 27 to 52).  Its absence identifies patients with a median eGFR of 69 mL/min per 
1.73 m2 (interquartile range 56 to 82). 35 
g Thyroid disease includes hypothyroidism, thyroiditis, iodine deficiency related thyroid disorders, nontoxic goiter, thyrotoxicosis, and other disorders of the thyroid. 
h Investigations were assessed by administrative codes in the previous five years. 
i Diabetes management is an all-inclusive service payable to the most responsible physician for providing continuing management and support of a diabetic patient. The service must 
include assessments focusing on diabetic target organ systems, relevant counseling and maintenance of a diabetic flow sheet retained on the patient’s permanent medical record. The 
flow sheet must track lipids, cholesterol, HbA1C, urinalysis, blood pressure, fundal examination, peripheral vascular examination, weight, body mass index and medication dosage.36 
j Diabetes management incentive is a fee rendered to a general practitioner providing ongoing management of a diabetic patient consistent with the requirements of the Canadian 
Diabetes Association including a minimum of lipid, HbA1C, blood pressure, body mass index measurement, albumin:creatinine, preventative measures and health promotion, referral 
for dilated eye exam, foot and neurological exam over the previous 12 months.36 
k Baseline medication use was assessed in the previous 120 days.  
Less than 5% received prescriptions for atypical antipsychotics, clarithyromycin, fibrates, gatifloxacin or sulphonamides. Less than 1% received prescriptions for 
tacrolimus/sirolimus chloramphenicol, cyclosporine, disopyramine, isoniazid, probenicid, rifampin, aprepitant, protease inhibitors, danazol, valproic acid, monoamine oxidase 
inhibitors, aliskerin, amiodarone, androgens, barbiturates, carbamazepine, clonidine, fluconazole/voriconazole or tetracycline. There were no prescriptions for acetohexamide, 
pegvisimont, colesevelam, reserpine, guanethidine, ifosfamide, phenylbutazone, diazoxide or bosentan.  
l Drug dose level 1=glyburide 5mg/modified release gliclazide 30mg, 2=glyburide 10mg/ modified release gliclazide 60mg, 3=glyburide 15mg/ modified release gliclazide 90 mg,  
4=glyburide 20mg/modified release gliclazide 120 mg. 
m Where available, laboratory data was collected in the 1 year previous. 
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Table 5: Ninety-day outcomes in the monotherapy study 
 Number of Events (%) Risk 
Difference 
(%) (95% CI) 
NNH (95% 
CI) 
Conditional 
OR (95% CI) 
p-value 
 Glyburide  
n=4374 
 
 
Gliclazide  
n=4374 
 
 
Hospital 
encounter with 
hypoglycemia 
69 (1.58%) 8 (0.18%)  1.40% (1.01% 
to 1.79%) 
71 (55 to 99) 8.63 (4.15 to 
17.93) 
<0.0001 
All-cause 
mortality 
100 (2.29%)  84 (1.92%)  0.37% (-0.21% 
to 0.95%) 
 (…) 1.21 (0.89 to 
1.63) 
0.22 
 
Patients prescribed gliclazide served as the referent group. 
Abbreviations: NNH Number needed to harm 
 (…) NNH not significant.  
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Table 6: Ninety-day outcomes in the metformin combination study 
 Number of Events (%) Risk Difference 
(%) (95% CI) 
NNH (95% 
CI) 
Conditional 
OR (95% 
CI) 
p-value 
 Glyburide  
n=8038 
 
 
Gliclazide  
n=8038 
 
 
Hospital encounter 
with hypoglycemia 
110 (1.37%) 19 (0.24%)  1.13% (0.86% to 
1.40%) 
77 (71 to 116) 6.06 (3.68 to 
9.97) 
<0.0001 
All-cause mortality 109 (1.36%)  75 (0.93%)  0.43% (0.10% to 
0.76%) 
233 (131 to 
1000) 
1.47 (1.09 to 
1.97) 
0.012 
 
Patients prescribed gliclazide served as the referent group 
Abbreviations: NNH Number needed to harm 
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Chapter 3 
3 Trends in antihyperglycemic medication prescriptions and 
hypoglycemia in older adults: 2002-2013 
Kristin K Clemens, MD 1; Salimah Shariff, PhD 2; Kuan Liu, MMath 2; Irene Hramiak, MD 3; 
Jeffrey L Mahon, MD 3,4; Eric McArthur, MSc 2 ; Amit X. Garg, MD PhD 1,2,4 
1. Department of Medicine, Western University, London Ontario Canada 
2. Institute for Clinical Evaluative Sciences, London Ontario Canada 
3. Department of Medicine, Division of Endocrinology, Western University, London Ontario 
Canada 
4. Department of Epidemiology and Biostatistics, Western University, London Ontario Canada 
3.1 Introduction 
The management of glycemic control in older patients with type 2 diabetes has become 
increasingly complex over the last decade.1 First, where only sulfonylureas (eg. glyburide), 
insulin, alpha glucosidase inhibitors (eg. acarbose), and biguanides (eg. metformin) were 
accessible in Canada in the 1990’s, there are now 9 classes of medications and at least 20 unique 
drugs and their combinations available to control hyperglycemia. Second, while all drugs by 
design lower glucose levels, there are important differences among them with respect to their 
other known or suspected advantages and risks. Of particular importance in older patients are 
differences among the medications in risk for hypoglycemia.2–4 Third, while randomized trials 
have established the benefit of intensified glycemic control in reducing risk for microvascular 
complications, it remains unclear as to whether this also leads to an important reduction in risk 
for macrovascular complications and, if so, whether such benefit exceeds the risks of tighter 
control in all cases.5,6  
Given that there are limited data on how antihyperglycemic medications are being used in older 
patients with diabetes, in the current study we aimed to examine patterns in antihyperglycemic 
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medication prescriptions in this population from 2002 until 2013. As the hypoglycemia risk of 
these medications differ, we also examined their hospital encounters for hypoglycemia over the 
period of study.   
3.2 Methods 
3.2.1 Study design and setting 
We conducted population-based cross sectional analyses of older adults with diabetes from April 
1, 2002 until March 31, 2013, using linked health care databases in Ontario Canada. Ontario 
currently has a population of over 13 million people, of which 2 million are age 65 years or 
older.7 In our province, people over the age of 65 have universal coverage for outpatient 
prescription medications, physician services, hospitalizations and investigations.8  
Databases were linked using unique, encoded identifiers and were analyzed at the Institute for 
Clinical Evaluative Sciences according to a pre-specified protocol. The study was approved by 
the research ethics board at Sunnybrook Health Sciences Centre (Toronto, Canada). Participant 
informed consent was not required. 
We divided our study timeframe into 3-month intervals (study quarters). We report this study 
using guidelines for observational studies (checklist of recommendations presented in Appendix 
D Table 1).9 
3.2.2 Data sources 
We used 6 databases to examine patient characteristics, drug use, covariate information, and 
outcomes. To identify patients with diabetes, we used the Ontario Diabetes Database (ODD), a 
previously validated electronic registry with 86% sensitivity and 97% specificity to detect 
diabetes.10 The Registered Persons Database of Ontario was used to collect vital statistics. It 
contains demographic information for all Ontario residents who have ever been issued a health 
card. We used the Ontario Drug Benefit Program database to examine prescription medications 
as in our province, adults age 65 and older are eligible for drug coverage, and the information on 
these prescribed medications is accurately contained within this database (error rate of less than 
1%).11 Diagnostic and procedural information on hospitalizations and emergency room visits was 
obtained from the Canadian Institute for Health Information’s Discharge Abstract Database and 
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the National Ambulatory Care Reporting System database. We obtained additional covariate 
information from the Ontario Health Insurance Plan database, which includes health claims for 
inpatient and outpatient physician services. A subpopulation had outpatient glycosylated 
hemoglobin (HbA1c) values available in the 1 year prior to the relevant study quarter. 
International Classification of Diseases 9th revision (ICD-9, pre-2002), 10th Revision (ICD-10, 
post-2002), Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures (CCP, 
pre-2002) and Canadian Classification of Health Interventions (CCI, post-2002) codes were used 
to assess baseline comorbidities in the 5 years prior to 3 study quarters (administrative codes 
listed in Appendix D Table 2). Codes utilized to ascertain hypoglycemia encounters are detailed 
in Appendix D Table 3, which lists only ICD-10 codes as all events would have occurred after 
the implementation of this coding system in Canada. 
3.2.3 Patients 
During each quarter, we identified all adults with diabetes as defined by the ODD. We then 
excluded the following patients from analysis: 1) those with a missing age or sex, invalid age 
(over 105 years) or death recorded on or before the beginning of the quarter (for data cleaning 
purposes), 2) non-Ontarian residents at the beginning of each quarter (to allow for adequate 
patient follow-up), and 3) those under the age of 66 (as the province’s drug formulary provides 
prescription coverage to those over the age of 65 and to avoid incomplete medication records in 
their first year of eligibility).  
We defined patients with treated diabetes as those who had evidence of at least 1 
antihyperglycemic prescription (including insulin or an oral antihyperglycemic medication) 
during the study quarter, insulin users as those with evidence of at least 1 prescription for insulin 
during the study quarter, and patients with newly treated diabetes as those who had evidence of 
at least 1 antihyperglycemic medication prescription during the quarter with no evidence of a 
previous prescription for any agent in the 1 year prior. Monotherapy users had evidence of only 1 
antihyperglycemic medication prescription during the relevant quarter and combination users had 
evidence of more than 1 prescription. 
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3.2.4 Outcomes 
For the primary outcome, we examined the percentage of treated and newly treated patients with 
a prescription for insulin, sulphonylureas, alpha-glucosidase inhibitors, metformin, 
thiazolidinediones, meglitinides, and dipeptidyl peptidase-4 inhibitors (DPP-4). These 
antihyperglycemic medications are the only agents currently covered by our provincial drug 
formulary. For our secondary outcome we examined the percentage of treated patients with a 
hospital encounter with hypoglycemia (emergency room visit or inpatient admission) during 
each quarter of study. 
3.2.5 Statistical analysis 
We used descriptive statistics to summarize the baseline characteristics of patients with treated 
and newly treated diabetes at the beginning of three study quarters (April 1 2002, April 1, 2007, 
April 1, 2012). The percentage of patients prescribed each antihyperglycemic medication during 
the relevant quarter was calculated by dividing the total number with a prescription (numerator) 
by the total number of treated patients (or newly treated patients) (denominator) during the 
quarter. The percentage of patients with a hypoglycemia encounter during each quarter was 
determined by dividing the total number of patients with at least 1 encounter (numerator) by the 
total number of treated patients (denominator). We conducted all analyses with SAS version 9.3 
(SAS Institute, Cary, North Carolina). 
3.3 Results 
Over the decade from April 2002 until March 2013, the number of patients with treated diabetes 
almost doubled from 148,021 to 289,312 individuals (Figure 1). The baseline characteristics of 
treated and newly treated patients are presented in Table 7 and Appendix D Table 4 respectively. 
In both groups, their mean age remained stable over the study quarters as did the proportion that 
were female. With the exception of chronic kidney disease, the percentage with a diabetes-
related comorbidity appeared to decline. Where available for a sub-population of included 
patients, HbA1c values appeared to increase slightly (Table 7 and Appendix D Table 4). 
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3.3.1 Patients with treated diabetes 
Figure 2 shows the percentage of patients with treated diabetes with a prescription for insulin, 
sulphonylureas, alpha-glucosidase inhibitors, metformin, meglitinides, thiazolidinediones and 
DPP-4 inhibitors from 2002 until 2013.   
The percentage prescribed metformin increased over the study period (56.17% in first quarter, 
76.51% in last quarter), as did prescriptions for the DPP-4 inhibitors saxagliptin (prescriptions 
increased from 0% to 1.79% following its formulary introduction in 2012) and sitagliptin 
(prescriptions increased from 0% to 18.09% following its formulary introduction in 2010).  A 
decline in glyburide prescriptions was evident (56.43% in the first quarter, 10.65% in the last 
quarter), while gliclazide prescriptions increased (prescriptions increased from 0.40% to 24.30% 
following the formulary introduction of modified-release gliclazide in 2007). Over the last 10 
years about 20% of treated patients have been prescribed insulin. Further, after an initial increase 
following their introduction to the provincial formulary in 2006/2007, thiazolidinedione 
prescriptions declined, although pioglitazone did so less steeply than rosiglitazone. Prescriptions 
for acarbose, acetohexamide, glimepiride, repaglinide, tolbutamide, nateglinide, and 
chlorpropamide have remained low (less than 5% of patients had evidence of a prescription 
during each study quarter). 
Antihyperglycemic mono and combination therapy is illustrated in Appendix D Figure 1 and 2. 
Over the last decade, there was a small decrease in the percentage of patients prescribed 
monotherapy (including insulin monotherapy), and a small increase in those prescribed three or 
more agents (including in insulin users). The oral antihyperglycemic medications prescribed in 
insulin users are illustrated in Appendix D Figure 3. 
3.3.2 Patients with newly treated diabetes 
New antihyperglycemic medication prescriptions are illustrated in Appendix D Figure 4. The 
majority of patients were prescribed metformin (approximately 80%), with a small percentage 
decrease noted from July 2006 until April 2008. The percentage of patients prescribed the DPP-4 
inhibitors increased (prescriptions for sitagliptin increased from 0% to 10.10% following its 
introduction to the formulary; saxagliptin prescriptions increased from 0% to 2.08% following its 
introduction to the formulary). We also note that fewer of these patients were initiated on 
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glyburide over time, (38.99% in the first quarter and 2.90% in the last quarter) with an increasing 
number initiated on gliclazide (prescriptions increased from 0.26% to 11.69% following the 
introduction of modified-release gliclazide to the formulary). Insulin use remained relatively 
stable (approximately 7%). Further, although thiazolidinedione prescriptions initially rose in 
2006/2007, they have since decreased. Prescriptions for acarbose, acetohexamide, glimepiride, 
repaglinide, tolbutamide, nateglinide, and chlorpropamide remained low (less than 5% of 
patients had evidence of a prescription during each study quarter).   
Where mono- and combination therapy was examined in newly treated patients, there was a 
slight decrease in monotherapy (including insulin monotherapy) and an increase in combination 
therapy over time (including insulin combination therapy) (Appendix D Figure 5 and 6). 
3.3.3 Hypoglycemia 
In the setting of these prescription trends, the absolute number of treated patients with a 
hypoglycemia encounter increased until mid-2006 and then declined. However, when the 
increasing prevalence of treated diabetes was accounted for, the percentage with a hospital 
encounter with hypoglycemia declined by 50% over the decade (0.79% with an event in the first 
quarter, 0.41% with an event in the last quarter). (Figure 3) 
3.4 Discussion 
3.4.1 Principal findings and main implications 
In this study we have identified several trends in antihyperglycemic medication prescriptions in 
patients with diabetes age 66 and older in Ontario.  
First, over the last decade there has been a substantial increase in the number of older adults 
using antihyperglycemic medications in our province. Whether this increase is due to an 
increased detection of diabetes, an aging population, or a higher number of individuals with 
obesity and sedentary lifestyle remains to be determined.  
Second, consistent with guidelines which recommend metformin as a first line agent for its 
efficacy, safety, weight effects, and possible cardiovascular benefit,12,13 metformin remains the 
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most commonly prescribed antihyperglycemic medication among older adults in Ontario. This 
result is consistent with high rates of metformin use in other jurisdictions.14–18  
Third, we found that prescriptions for glyburide steadily declined over the last decade whereas 
those for gliclazide have increased. This change is consistent with clinical practice guidelines 
which have endorsed avoiding glyburide in older patients in favour of sulphonylureas including 
gliclazide that have a lower risk for hypoglycemia. 19  
Fourth, since their addition to the drug formulary, prescriptions for both pioglitazone and 
rosiglitazone have declined. These findings may reflect safety concerns that have arisen with 
these medications,20–23 regulatory advisories (Appendix D Table 5), and funding status changes 
in our province (thiazolidinediones transferred from the unrestricted formulary to the exceptional 
access program in in June 2009). 24,25 Pioglitazone currently remains more commonly prescribed 
than rosiglitazone perhaps reflecting evidence of its better safety profile compared with its 
counterpart.26–28 Consistent with the findings of research in other regions, we also note that there 
has been an uptake of new medications including the DPP-4 inhibitors.14,17,18   
Fifth, we found that that combination therapy has increased over time, including in newly treated 
patients. It is possible that clinical trials that have suggested the benefit of intensive glycemic 
control in the prevention of microvascular complications have been contributory,5,6 along with 
the possibility of personalizing therapy with several drugs in order to achieve better control.16 
Further, published reports have noted that combination therapy at submaximal doses may help to 
improve glycemic control more rapidly and with fewer side effects than monotherapy,13,29–31 and 
practice guidelines suggest that combination therapy be initiated in patients with higher 
HbA1c’s.13 
Finally, in the setting of these prescription trends, the overall percentage of treated patients with 
a hospital encounter for hypoglycemia has declined in our region. Our findings are consistent 
with a recent study of United States Medicare beneficiaries (1999 to 2011). When the changing 
prevalence of diabetes was accounted for by the authors, admissions for hypoglycemia decreased 
by 9.5%.32 Although a decline in the use of glyburide and the uptake of agents associated with a 
lower hypoglycemic risk may have contributed to this trend, other factors including changes in 
the accuracy of diagnostic coding, diabetes screening, quality of patient care and education, 33 
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secular trends in glycemic control, and the characteristics of patients with the disease 
(comorbidities, functional limitations, self-management behavior), may have also played a role. 
32,34
 
3.4.2 Strengths and limitations 
Compared with previous drug trend studies, our report has several strengths.18,24,25,27 First, we 
comprehensively examined all 15 antihyperglycemic medications currently covered by the 
provincial drug formulary and ascertained prescription trends in a variety of antihyperglycemic 
medication users (including those with treated and newly treated diabetes). Our decade of study 
also allowed for an assessment of medication trends during an era of changing diabetes care. 
Where previous studies have been limited to younger patients with diabetes, ours provided a 
perspective on prescribing practices in a more vulnerable population of older adults. We also 
detailed the demographic characteristics, comorbidities, and HbA1c values of included patients 
to help put prescribing practices into context. Finally, in the setting of changing prescription 
trends, we quantified both inpatient and emergency room hospital encounters with hypoglycemia 
– a serious adverse event in older patients.  
Our study has limitations. We were unable to capture antihyperglycemic medication 
prescriptions not covered by our provincial formulary (including glucagon like peptide-1 
agonists and sodium glucose co-transporter 2 inhibitors). Although we expect our results to be 
generalizable to the elderly with publically funded healthcare, we cannot extend our results to 
those under the age of 65 or on other drug funding schemes where variations in drug prescribing 
have been noted.  
Our databases also did not allow us to evaluate diabetes type, although given their age and the 
prevalence of type 2 diabetes, the majority of patients may have had type 2 diabetes. Further, we 
could not capture their duration of diabetes which can influence treatment choices and diabetes-
related complications.34   
For our outcome of hypoglycemia, we were unable to assess events experienced outside of the 
hospital, including emergency medical service contacts or home events that did not lead to 
hospital presentation. Additionally, we assessed the outcome of hypoglycemia with 
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administrative codes which have limited sensitivity when compared to laboratory plasma glucose 
measurements (although the latter is not the best reference standard as treatment with glucose 
may have been initiated by the time plasma glucose is measured). Further, although we do note a 
decline in the use of glyburide and the uptake of safer medications, these data do not prove that 
prescription changes led to a decline in the rates of hypoglycemia. Although we did measure 
comorbidities and demographic characteristics that are associated with hypoglycemia, we were 
also unable to account for changes in health literacy, attitudes, and social support which could 
cause differences in the likelihood of seeking medical care.33 
3.4.3 Conclusions 
Antihyperglycemic medication prescribing practices have changed significantly in Ontario over 
the last 11 years. In the setting of a decline in the use of glyburide, and the uptake of drugs with a 
lower hypoglycemia risk, there has been a decrease in the percentage of treated patients with a 
hospital encounter for hypoglycemia in our region. The extent to which this reduction is related 
to the use of safer medication or to other factors remains to be established. 
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Table 7. Baseline characteristics of patients with treated diabetes  
 April 1, 2002 April 1, 2007 April 1, 2012 
  N= 148,021 % N=212,538 % N=288,866 % 
Age (yr)             
Mean (SD) 74.74 (6.28)   75.13 (6.48)   75.40 (6.80)   
Median   
(IQR) 
74 (70-79) 
  
74(70-80) 
  
74 (70-80) 
  
66-69 35,472 23.96% 49,710 23.39% 69,073 23.91% 
70-74 44,063 29.77% 59,111 27.81% 76,954 26.64% 
75-79 35,821 24.20% 50,384 23.71% 63,877 22.11% 
80-84 20,465 13.83% 33,387 15.71% 45,993 15.92% 
85-89 9105 6.15% 14,839 6.98% 24,064 8.33% 
90+ 3095 2.09% 5107 2.40% 8905 3.08% 
Sex - Female 76,456 51.65% 107,187 50.43% 140,884 48.77% 
Income quintile             
Missing 465 0.31% 809 0.38% 1188 0.41% 
1 (lowest) 35,308 23.85% 49,607 23.34% 62,975 21.80% 
2 34,709 23.45% 47,862 22.52% 63,610 22.02% 
3 29,639 20.02% 41,770 19.65% 57,919 20.05% 
4 25,418 17.17% 38,819 18.26% 55,395 19.18% 
5 (highest) 22,482 15.19% 33,671 15.84% 47,779 16.54% 
Rural              
Missing 72 0.05% 72 0.03% 122 0.04% 
No 125,609 84.86% 183,482 86.33% 250,090 86.58% 
Yes 22,340 15.09% 28,984 13.64% 38,654 13.38% 
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 April 1, 2002 April 1, 2007 April 1, 2012 
  N= 148,021 % N=212,538 % N=288,866 % 
Comorbiditiesa             
Chronic kidney 
disease 15,277 10.32% 24,665 11.60% 41,473 14.36% 
Chronic liver 
disease 5650 3.82% 7963 3.75% 10,577 3.66% 
Any cancer 37,955 25.64% 55,425 26.08% 79,749 27.61% 
Coronary heart 
disease 
(excluding 
angina) 55,221 37.31% 73,074 34.38% 86,904 30.08% 
Congestive heart 
failure 30,419 20.55% 36,450 17.15% 43,059 14.91% 
Peripheral 
vascular disease 6000 4.05% 5666 2.67% 4706 1.63% 
Dementia 14,096 9.52% 23,644 11.12% 35,577 12.32% 
Stroke/TIA 8182 5.53% 8478 3.99% 9329 3.23% 
Neuropathy 1640 1.11% 2683 1.26% 4085 1.41% 
Retinopathy 5172 3.49% 4964 2.34% 4563 1.58% 
Investigationsb       
Mean (SD) 
number 
cholesterol tests 
 1.06 (1.26) --- 1.31 (1.26) --- 1.40 (1.19) --- 
Median (IQR) 
cholesterol tests 1 (0-2) --- 1 (0-2) --- 1 (1-2) --- 
Mean (SD) 
HbA1c tests 1.88 (1.9) --- 2.04 (1.73) --- 2.21 (1.56) --- 
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 April 1, 2002 April 1, 2007 April 1, 2012 
  N= 148,021 % N=212,538 % N=288,866 % 
Median (IQR) 
HbA1c tests 2 (0-3) --- 2 (1-3) --- 2 (1-3) --- 
Mean (SD) 
creatinine tests 1.93 (2.32) --- 2.23 (2.33) --- 2.41 (2.25) --- 
Median (IQR) 
creatinine tests 1 (0-3) --- 2 (1-3) --- 2 (1-3) --- 
Mean (SD) 
glucose tests 2.68 (3.25) --- 2.34 (2.46) --- 2.18 (1.95) --- 
Median (IQR) 
glucose tests 2 (1-4) --- 2 (1-3) --- 2 (1-3) --- 
At least 1 eye 
exam 61,157 41.32% 81,240 38.22% 97,025 33.59% 
Laboratory Datac       
At least 1 HbA1c 
outpatient lab 
value --- --- 53,239 25.05% 75,311 26.07% 
Mean (SD) 
HbA1c (%) --- --- 7.0% (1.2%) --- 7.2% (1.2%) --- 
Mean (SD) 
HbA1c 
(mmol/mol)   53 (13.1)  55 (13.1)  
Median (IQR) 
HbA1c --- --- 
6.8% (6.2%-
7.5%) --- 
7.0% (6.5%-
7.7%) --- 
Mean (SD) 
HbA1c 
(mmol/mol)   51 (44-58)  53 (48-61)  
Abbreviations: TIA transient ischemic attack, SD standard deviation, IQR interquartile range, 
HbA1c hemoglobin A1c 
aComorbidities were examined in the 5 years prior. 
bInvestigations were examined in the 1 year prior. 
cLab values were available in the 1 year prior. 
68 
68 
 
Figure 1. The number of patients with treated diabetes has nearly doubled over the last 
decade (2002-2013) 
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Figure 2. Antihyperglycemic medication prescriptions 2002
*Drugs prescribed to less than 5% not illustrated (acarbose, acetohexamide, chlorpr
glimepiride, nateglinide, repaglinide, tolbutamide)
Abbreviations: TZD thiazolidinediones
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Figure 3. Hospital encounters for hypoglycemia in treated patients 2002-2013 
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Chapter 4 
4 Discussion 
4.1 Main findings 
In the current work we investigated antihyperglycemic medication prescribing and safety in older 
adults with diabetes. 
We first note that even within the same drug class (sulphonylureas), the hypoglycemia risk of 
antihyperglycemic medications differ significantly in routine care. In 2 matched retrospective 
cohort studies of older adults newly prescribed glyburide or modified-release gliclazide as 
monotherapy or in the presence of metformin, we found that the hypoglycemia risk of glyburide 
was over 500% greater than modified-release gliclazide. 
Given the increasing availability of antihyperglycemic medications with different safety profiles, 
we then carried out an ecological study to examine patterns in antihyperglycemic medication 
prescriptions in older adults from 2002 until 2013. Here we note that there has been increasing 
uptake of safer medications (including gliclazide) in our region. In this setting, there has been a 
decline in the overall percentage of treated patients with an encounter for hypoglycemia. 
Although the decline in hypoglycemia observed in recent years may relate to the use of 
medications with a lower hypoglycemia risk, additional factors may have also contributed 
including changing quality of care, the accuracy of administrative codes, or the characteristics of 
patients with the diabetes (ie. their duration of disease, comorbidities etc.).  
4.2 General strengths and limitations 
There are several strengths to our current work. First, as our studies were observational in design, 
we were able to examine a population of older adults with comorbidities who are frequently 
excluded from randomized controlled trials. This makes our work generalizable to a larger 
population.1,2 Where clinical trials are often limited in their sample size, we were also able to 
efficiently study a large sample of these individuals (up to 289,312 in the last quarter of our 
antihyperglycemic medication trends investigation).1    
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Second we were able to draw upon the rich data contained within Ontario’s health administrative 
databases.  Ontario’s health administrative databases are a unique combination of the province’s 
large population and Canada’s universal health care coverage. The data is recognized for its 
comprehensiveness (includes all Ontario residents, vital statistics, physician claims, 
hospitalizations and medical procedures), retention (loss to follow-up from emigration is 
<0.5%/year), and accuracy (validity of key elements such outpatient drug claims prescribed to 
older people). 
There are some weaknesses of our work that warrant attention. First, for our glyburide vs 
gliclazide drug study, prospective data collection with independent outcome adjudication would 
have been a preferred methodology to a retrospective database study. Our trends study was 
additionally a general descriptive study and we collected data on groups and not for each 
individual within the population. We thus could not determine whether the individuals in whom 
hypoglycemia developed were on the agents associated with a higher hypoglycemia risk. As a 
result, we could not establish a causal association between drug use and hypoglycemia.3  
Second, the potential biases in our studies warrant attention. In our glyburide vs gliclazide study, 
our non-random exposure allocation may have led to “indication bias”, a bias frequently 
encountered in pharmacoepidemiologic studies. We did however did try to minimize this bias by 
using propensity score matching to help ensure that the distribution of measured baseline 
characteristics were similar between treated and untreated patients. 2,4 
Third, as in all observation studies, residual confounding is an additional consideration. This 
occurs where adjustment does not completely remove the confounding effect due to a given 
variable or a set of variables.5 In our glyburide vs gliclazide study we had no information on 
unmeasured factors such as nutrition, glucose monitoring, patient education, health literacy, 
attitudes, and social support which may have influenced the association between sulphonylurea 
type and outcome. However, using a matching technique we did obtain good balance on a large 
number of measured baseline characteristics between the two groups. As well, the magnitude of 
the relative risk of hypoglycemia in these studies were large making it unlikely the association 
can be entirely explained by confounding factors.  
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Fourth, although we used rich administrative databases to obtain our data, the variables captured 
within these databases may not be complete. For example, we were unable to assess medical 
conditions that did not result in hospital presentation or physician billing including hypoglycemia 
encounters that were self-treated in the home or by emergency medical service personnel. We 
were also unable to identify comorbidities, outcomes, and procedures that are not associated with 
a specific ICD or billing codes, and were only able to examine procedures covered by the 
universal health care system.1 The possibility of information bias thus arises, although we 
anticipate that this bias led to non-differential misclassification (ie. that not related to exposure 
status but due to a problem inherent in the data sources).2  
Fifth, although we could accurately ascertain medications dispensed, we had no information on 
medication use. We further could not assess over the counter medications or medications covered 
by private drug-funding schemes.   
Finally, we assessed the outcome of a hospital encounter with hypoglycemia with administrative 
codes which have limited sensitivity and accuracy compared to laboratory plasma glucose 
measurements (although the latter is not the best reference standard as treatment with glucose has 
frequently been initiated in many hypoglycemic episodes by the time plasma glucose is 
measured).  
4.3 Conclusions 
Antihyperglycemic medications are central to the management of patients with diabetes. These 
medications however have very different side effects including risks for hypoglycemia.   
In Ontario, there has been an uptake of newer and safer medications in older adults including 
gliclazide. In this setting, over the past decade there has been a decrease in the percentage of 
treated patients with a hospital encounter with hypoglycemia. The extent to which this finding 
relates to the use of safer prescription medications or to other factors remains to be determined.   
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4.4 Future research 
A closer examination of drug prescribing and safety in older adults with medical comorbidities is 
needed. This is especially important for those with chronic kidney disease (CKD).    
CKD is a common comorbidity in people with diabetes.6 Patients with CKD are often on 
multiple medications, have concomitant comorbidities, and have differences in drug metabolism 
and clearance. In this population, hypoglycemia is also a major concern due to diminished renal 
gluconeogenesis, and impaired clearance of antihyperglycemic medications.6,7   
Given their vulnerabilities, patients with CKD and diabetes need to be treated cautiously.8 
Unfortunately, there have been few clinical studies that have been published to assess or guide 
the management of this patient population. Our future research efforts then will focus on 
antihyperglycemic medication prescribing, safety and efficacy in patients with impaired renal 
function. 
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Appendix A  
Definitions of Key Terminology 
Angiotensin converting enzyme inhibitor – a medication that helps to relax blood vessels and 
decrease blood pressure.  
Angiotensin receptor blockers – a medication that helps to relax blood vessels and decrease 
blood pressure. 
Antihyperglycemic medications – medications that work to lower blood sugar. 
Antiplatelet therapy – medications that help to prevent the formation of blood clots. 
Autoimmune disease – disease where one’s immune system inappropriately attacks healthy body 
cells/tissues. 
Autonomic nerves –  nerves that help to control involuntary actions such as digestion, heart rate, 
and vessel tone. 
Bariatric surgery – weight-reduction surgery. 
Chronic kidney disease – chronic loss of kidney function. 
Cognitive function – involves one’s memory, language, thinking and judgment. 
Combination therapy – the use of 2 or more medications. 
Counter-regulatory response – body’s stress response to hypoglycemia, mediated by the release 
of hormones and neurotransmitters. 
Debridement – the removal of dead or damaged body tissue. 
Diabetic ketoacidosis – diabetes emergency that leads to hyperglycemia and the accumulation of 
ketones (breakdown product of fat). 
Diagnostic – concerned with the identification of an illness/process. 
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Dopamine antagonists – drugs which block the body’s dopamine receptors. 
Drug formulary – a collection of drugs funded by the province’s drug benefit program. 
Exceptional access program – program which facilitates the funding of medications that are not 
covered by the province’s drug benefit program. 
Exudate – fluid which escapes from the body’s blood vessels. 
Gangrene – condition which occurs when body tissue dies. 
Gastroparesis – impaired motility of the stomach. 
Glycemic control – control of blood sugar. 
Glycosylated hemoglobin (HbA1c)– laboratory measure which reflects blood sugar control over 
the previous 8-12 weeks. 
Health literacy - the ability to access, comprehend, evaluate and communicate health 
information. 
Hyperglycemia – high blood sugar. 
Hyperglycemic hyperosmolar state – diabetes emergency that leads to extremely high blood 
sugar and dehydration, without the accumulation of ketones. 
Hypoglycemia – low blood sugar. 
Hypoglycemia unawareness – occurs when one has greater tolerance to low blood sugar and does 
not feel its associated symptoms. 
Insulin – hormone responsible for the storage and utilization of glucose in the body. 
Insulin deficiency – lack of insulin. 
Insulin resistance – poor utilization of insulin. 
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Intensive glycemic control – blood sugar control that targets a glycosylated hemoglobin less than 
7%. 
Ischemia – lack of oxygen to a tissue. 
Lipid disorder – abnormality of cholesterol and triglycerides. 
Lipid lowering medications – medications that work to lower cholesterol and triglycerides. 
Macrovascular disease – disease of the large blood vessels of the body (ie. heart, brain, 
periphery). 
Macular edema – occurs when fluid leaks from the blood vessels in the eyes. 
Metabolic condition – disease caused by a disruption in the chemical reactions in the body. 
Microvascular disease – disease of the small blood vessels of the body (ie. eyes, kidney, nerves). 
Microaneurysms – small aneurysm or swelling of the blood vessels in the eye. 
Monotherapy – the use of 1 medication. 
Motor nerves – nerves that act on the muscles. 
Nephropathy – damage to the kidneys. 
Neuropathy – damage to the nerves of the body. 
Number needed to harm - estimate of how many people need to receive a treatment before one 
more person would experience a harmful outcome. 
Odds ratio – the ratio of odds of the development of disease in exposed people to the odds of the 
development of disease in unexposed people. 
Oral glucose tolerance test – a test which measures how well the body breaks down sugar. 
Pancreatic beta cell – cell of the pancreas that is responsible for the production of insulin. 
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Photocoagulation- a surgical procedure which involves the clotting of eye tissue with a laser. 
Procedural – refers to a task or operation. 
Relative risk – describes disease risk in exposed people relative to the disease risk in unexposed 
people. 
Retinopathy – disease of the eyes. 
Retinal detachment – occurs when the retina (eye tissue) separates from the back of the eye. 
Risk difference – difference in observed risks between groups. 
Sensory nerves – nerves that transmit sensation information. 
Structural complications – refer to the microvascular and macrovascular complications of 
diabetes. 
Urinary incontinence- the loss of bladder control. 
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Table 1: Checklist of recommendations for reporting of observational studies using the 
STROBE guidelines 
 
 Item 
No Recommendation Reported 
 Title and abstract 1 
(a) Indicate the study’s design with a commonly used 
term in the title or the abstract Abstract 
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found Abstract 
Introduction 
 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported Introduction 
Objectives 3 State specific objectives, including any pre-specified hypotheses Introduction 
Methods 
 
Study design 4 Present key elements of study design early in the paper Methods 
Setting 5 
Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-up, 
and data collection 
Methods 
Participants 6 
(a) Give the eligibility criteria, and the sources and 
methods of selection of participants. Describe methods 
of follow-up 
Methods 
(b) For matched studies, give matching criteria and 
number of exposed and unexposed Methods 
Variables 7 
Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable 
Methods 
Data sources/ 
measurement 8 
 For each variable of interest, give sources of data and 
details of methods of assessment (measurement). 
Describe comparability of assessment methods if there 
is more than one group 
Appendix B Table 2 
and 3 
Bias 9 Describe any efforts to address potential sources of bias Discussion 
Study size 10 Explain how the study size was arrived at 
Methods, based on 
availability of the 
data 
Quantitative 
variables 11 
Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were 
chosen and why 
Methods 
Statistical methods 12 
(a) Describe all statistical methods, including those 
used to control for confounding Methods 
(b) Describe any methods used to examine subgroups 
and interactions Methods 
(c) Explain how missing data were addressed Not Applicable 
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(d) If applicable, explain how loss to follow-up was 
addressed Not Applicable 
(e) Describe any sensitivity analyses Methods 
Results 
 
Participants 13 
(a) Report numbers of individuals at each stage of 
study—e.g. numbers potentially eligible, examined for 
eligibility, confirmed eligible, included in the study, 
completing follow-up, and analyzed 
Results, Appendix B 
Figure 1 and 2 
(b) Give reasons for non-participation at each stage Appendix B Figure 1 
and 2 
(c) Consider use of a flow diagram 
Appendix B Figure 1 
and 2 
 
 
 
Descriptive data 14 
(a) Give characteristics of study participants (e.g. 
demographic, clinical, social) and information on 
exposures and potential confounders 
Results, Table 3 and 
4 
(b) Indicate number of participants with missing data 
for each variable of interest Results 
(c) Summarize follow-up time (e.g. average and total 
amount) Results 
Outcome data 15 Report numbers of outcome events or summary 
measures over time Results 
Main results 16 
(a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision (e.g. 
95% confidence interval). Make clear which 
confounders were adjusted for and why they were 
included 
Results, Table 5 and 
6 
(b) Report category boundaries when continuous 
variables were categorized Table 3 and 4 
(c) If relevant, consider translating estimates of relative 
risk into absolute risk for a meaningful time period 
Results, Table 5 and 
6 
Other analyses 17 Report other analyses done—e.g. analyses of subgroups 
and interactions, and sensitivity analyses Results 
Discussion 
 
Key results 18 Summarize key results with reference to study 
objectives Discussion 
Limitations 19 
Discuss limitations of the study, taking into account 
sources of potential bias or imprecision. Discuss both 
direction and magnitude of any potential bias 
Discussion 
Interpretation 20 
Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other relevant 
evidence 
Discussion 
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Generalizability 21 Discuss the generalizability (external validity) of the 
study results Discussion 
Other information 
 
Funding 22 
Give the source of funding and the role of the funders 
for the present study and, if applicable, for the original 
study on which the present article is based 
Cover page, 
Disclosures 
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Table 2: Coding definitions for demographic and comorbid conditions 
 
Characteristics/Condition Database Codes 
 
  
Age RPDB 
 
Sex RPDB 
 
Socioeconomic Status Statistics Canada 
 
Rural Location Statistics Canada 
 
Long Term Care Utilization ODB 
 
Charlson Comorbidity Index CIHI-DAD 
 
Health Care Visits OHIP 
IPDB 
 
Prescribing Physician IPDB 
 
Alcoholism CIHI-DAD 
 
ICD 9: 303, 3050 
  
ICD 10: E24, E512, F10, G312, G621, G721, 
I426, K292, K70, K860, T510, X45, X65, Y15, 
Y573, Z502, Z714, Z721 
 
Chronic Kidney Disease CIHI-DAD 
 
 
 
 
 
OHIP 
ICD 9: 4030, 4031, 4039, 4040, 4041, 4049, 585, 
586, 5888, 5889, 25040 
 
ICD 10: E102, E112, E132, E142, I12, I13, N08, 
N18, N19 
 
OHIP DX: 403, 585 
Chronic Liver Disease CIHI-DAD 
 
 
 
 
 
 
 
 
 
OHIP 
ICD 9: 4561, 4562, 070, 5722, 5723, 5724, 5728, 
573, 7824, V026, 2750, 2751, 7891, 7895, 571 
 
ICD 10: B16, B17, B18, B19, I85, R17, R18, 
R160, R162, B942, Z225, E831, E830, K70, 
K713, K714, K715, K717, K721, K729, K73, 
K74, K753, K754, K758, K759, K76, K77 
 
OHIP DX: 571, 573, 070 
 
OHIP FEE: Z551, Z554 
Carotid Ultrasound CIHI-DAD 
 
 
 
OHIP 
CCP: 0281 
 
CCI: 3JE30 
 
OHIP FEE: J201, J501, J189, J489, J190, J191, 
J490, J491, J492 
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Coronary Angiogram CIHI-DAD 
 
 
 
 
OHIP 
 
CCP: 4892, 4893, 4894, 4895, 4896, 4897, 4898, 
4996, 4997 
 
CCI: 3IP10 
 
OHIP FEE: G297, Z442 
Coronary Revascularization CIHI-DAD 
 
 
 
OHIP 
CCP: 481, 482, 483, 480 
 
CCI: 1IJ50, 1IJ26, IIJ27, 1IJ57, 1IJ76 
 
OHIP FEE: R741, R742, R743, E651, E652, E654, 
E646, G298, Z434, G262 
Echocardiography CIHI-DAD 
 
 
 
OHIP 
CCP: 0282  
 
CCI: 3IP30 
 
OHIP FEE: G560, G561, G562, G566, G567, 
G568, G570, G571, G572, G574, G575, G576, 
G577, G578, G579, G580, G581 
Holter Monitoring CIHI-DAD 
 
OHIP 
CCI: 2HZ24JAKH 
 
OHIP FEE: G650, G651, G652, G653, G654, 
G655, G656, G657, G658, GG59, G660, G661, 
G682, G683, G684, G685, G686, G687, G688, 
G689, G690, G692, G693 
Stress Test CIHI-DAD 
 
 
 
OHIP 
CCP: 0341, 0342, 0343, 0344 
 
CCI: 2HZ08, 3IP70 
 
OHIP FEE: G315, G174, G111, G112, G319, 
J604, J606, J607, J608, J611, J612, J613, J667, 
J807, J808, J809, J804, J811, J812, J813, J867, 
J609, J666, J866 
Glycosylated Hemoglobin Test OHIP OHIP FEE: L093 
Diabetic Retinopathy CIHI-DAD ICD 9: 3602, 2505 
 
ICD 10: E1030, E1031, E1032, E1033, E1130, 
E1131, E1132, E1133, E1330, E1331, E1332, 
E1333, E1430, E1431, E1432, E1433, H360 
Diabetes Management OHIP OHIP FEE: K030 
Diabetes Incentive OHIP OHIP FEE: Q040 
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Coronary Artery Bypass Graft CIHI-DAD CCI: 1IJ50, 1IJ76 
 
CCP: 4802, 4803, 4809, 4811, 4812, 4813, 4814, 
4815, 4816, 4817, 4819 
 
OHIP FEE: Z434, R742, R743 
Peripheral Vascular Disease  CIHI-DAD 
 
 
 
 
 
 
 
 
OHIP 
ICD 9: 4402, 4408, 4409, 5571, 4439, 444 
 
ICD 10: I700, I702, I708, I709, I731, I738, I739, 
K551 
 
CCP: 5125, 5129, 5014, 5016, 5018, 5028, 5038 
 
CCI: 1KA76, 1KA50, 1KE76, 1KG26, 1KG50, 
1KG57, 1KG76MI, 1KG87 
 
OHIP FEE: R787, R780, R797, R804, R809, 
R875, R815, R936, R783, R784, R785, E626, 
R814, R786, R937, R860, R861, R855, R856, 
R933, R934, R791, E672, R794, R813, R867, 
E649 
Heart Failure CIHI-DAD 
 
 
 
 
 
 
 
 
OHIP 
ICD 9: 425, 5184, 514, 428 
 
ICD 10: I500, I501, I509, I255, J81 
 
CCP: 4961, 4962, 4963, 4964 
 
CCI: 1HP53, 1HP55, 1HZ53GRFR, 1HZ53LAFR, 
1HZ53SYFR 
 
OHIP FEE: R701, R702, Z429 
 
OHIP DX: 428 
Sepsis CIHI-DAD 
 
 
 
 
OHIP 
ICD 9: 0031, 0380, 0381, 0382, 0384, 0388, 0389, 
0545 
 
ICD 10: A40, A41, R572 
 
OHIP DX: 038 
Pituitary Disease CIHI-DAD 
 
 
 
OHIP 
ICD 9: 253, 2550 
 
ICD10: E22, E23, E24 
 
OHIP DX: 253 
Adrenal Disease CIHI-DAD 
 
ICD9: 2552, 2553, 2554, 2555, 2556, 2558, 2559, 
7591, 0363 
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OHIP 
 
ICD10: E25, E27, E351, Q891 
 
OHIP DX: 255 
Thyroid Disease CIHI-DAD 
 
 
 
OHIP 
ICD 9: 243, 244, 245, 246 
 
ICD 10: E01, E03, E04, E05, E06, E07 
 
OHIP DX: 242, 243, 244, 245 
Pancreatitis CIHI-DAD ICD 9: 5770, 5771, 0723 
 
ICD 10: K85, B252, B263, K860, K861 
Pancreatectomy CIHI-DAD CCI: 1OJ87, 1OJ89, 1OK87, 1OK89, 1OK91 
 
CCP: 6440, 6441,6442, 6443, 6449, 6450, 6460 
Pancreatic Cancer CIHI-DAD ICD 9: 1570, 1571, 1572, 1573, 1574, 1578, 1579 
 
ICD10: C250, C251, C252, C253, C254, C257, 
C258, C259 
 
OHIP DX: 157 
 
Abbreviations: CCI, Canadian Classification of Health Interventions; CIHI-DAD, Canadian Institute 
for Health Information Discharge Abstract Database; CCP, Canadian Classification of Diagnostic, 
Therapeutic and Surgical Procedures; ICD9, International Classification of Diseases, 9th revision; 
ICD10, International Classification of Diseases, 10th revision; IPDB, Institute for Clinical Evaluative 
Sciences Physician Database; OHIP DX, Ontario Health Insurance Plan Diagnostic Code; OHIP FEE, 
Ontario Health Insurance Plan Fee Code; RPDB, Registered Persons Database of Ontario. 
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Table 3: Coding definitions for hospital presentation with hypoglycemia and all-cause 
mortality  
 
Condition Database Codes 
Hypoglycemia a CIHI-DAD NACRS 
ICD10: E15, E160, E161, 
E162, E1063, E1163, 
E1363, E1463 
Mortality b RPDB Vital status field 
 
a
 We established a validation study of hypoglycemia codes in an emergency room or inpatient 
setting using linked laboratory plasma glucose values in Ontario.  In a cohort of 69,382 patients 
in the emergency room setting, hypoglycemia codes (ICD10: E15, E160, E161, E162, E1063, 
E1163, E1363, E1463) had a sensitivity of 21.8%, specificity of 99.5%, PPV 28.7%, NPV 99.2% 
for glucose values <3.9 mmol/L.  For glucose values <3.0 mmol/L, hypoglycemia codes had a 
sensitivity of 33.3%, specificity 99.4%, PPV 18.1%, NPV 99.7%. In a cohort of 47,377 patients 
admitted to hospital, hypoglycemia codes had a sensitivity of 7.3%, specificity 99.5%, PPV 
46.0%, NPV 94.9% for glucose values <3.9 mmol/L at the time of hospital presentation. For 
glucose values <3.0 mmol/L at the time of hospital presentation, hypoglycemia codes had a 
sensitivity 11.5%, specificity 99.4%, PPV 30.2%, and NPV 98.0%. We recognize laboratory 
plasma glucose values are not an ideal reference standard since in some instances hypoglycemia 
may have been treated by paramedics or the patient themselves prior to presenting to a hospital 
setting.   Furthermore, hypoglycemia may have been detected and treated based upon point of 
care capillary testing which may not have been documented in the laboratory setting. 
b Mortality has a sensitivity of 94% and a positive predictive value of 100%. See Jha P, Deboer 
D, Sykora K, Naylor CD. Characteristics and mortality outcomes of thrombolysis trial 
participants and nonparticipants: a population based comparison . J Am Coll Cardiol 1996; 
27:1335-42 
 
Abbreviations: CIHI-DAD, Canadian Institute for Health Information Discharge Abstract 
Database; ICD10, International Classification of Diseases, 9th revision; NACRS, National 
Ambulatory Care Reporting System Database; RPDB, Registered Persons Database of Ontario.  
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Table 4: Characteristics of patients with and without baseline laboratory values (serum 
creatinine or HbA1c) in the monotherapy and metformin combination study 
 
 Monotherapy Study 
 
Metformin Combination Study 
 
No lab 
values Lab values 
Standardized 
Difference 
 
No lab 
values 
 
Lab 
values 
Standardized 
Differencea 
Total 6744 2004 
 
11,663 4413  
Age at Index Date 
   
   
Mean (SD) 75.79 
(7.10) 
75.21 
(6.82)  
73.40 
(6.09) 
73.16 
(5.84)  
Median (IQR) 75 (70-81) 74 (69-80) 
 
72 (68-
77) 
72 (68-
77)  
66-70 years 1978 
(29.33) 615 (30.69) 3% 
4669 
(40.03) 
1804 
(40.88) 2% 
71-75 years 1600 
(23.72) 510 (25.45) 4% 
3161 
(27.10) 
1212 
(27.46) 1% 
76-80 years 1371 
(20.33) 427 (21.31) 2% 
2142 
(18.37) 
829 
(18.79) 1% 
81-85 years 1072 
(15.90) 271 (13.52) 7% 
1198 
(10.27) 
406 
(9.20) 4% 
86-90 years 544 (8.07) 138 (6.89) 4% 387 (3.32) 
141 
(3.20) 1% 
>90 179 (2.65) 43 (2.15) 3% 106 (0.91) 
21 
(0.48) 5% 
Female 
3331 
(49.39) 945 (47.16) 4% 
5397 
(46.27) 
2017 
(45.71) 1% 
Income based 
socioeconomic status b       
Quintile 1 
(lowest) 
1444 
(21.41) 431 (21.51) 0% 
2569 
(22.03) 
939 
(21.28) 2% 
Quintile 2 
1479 
(21.93) 492 (24.55) 6% 
2574 
(22.07) 
1012 
(22.93) 2% 
Quintile 3 
(middle) 
1352 
(20.05) 391 (19.51) 1% 
2379 
(20.40) 
919 
(20.82) 1% 
Quintile 4 
1315 
(19.50) 378 (18.86) 2% 
2219 
(19.03) 
821 
(18.60) 1% 
Quintile 5 
(highest) 
1154 
(17.11) 312 (15.57) 4% 
1922 
(16.48) 
722 
(16.36) 0% 
Rural Location 
851 
(12.62) 175 (8.73) 13% 
1550 
(13.29) 
478 
(10.83) 8% 
Data presented as number (percent) except where indicated. 
Abbreviations: HbA1c glycosylated hemoglobin, IQR interquartile range, SD standard deviation 
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a
 Standardized differences are less sensitive to sample size than traditional hypothesis tests. They 
provide a measure of the difference between groups divided by the pooled standard deviation; a 
value greater than 10% is interpreted as a meaningful difference between groups. 
b
 Income was categorized into fifths of average neighborhood income on the index date. 
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Table 5: Events in monotherapy study time to event analysis 
Censoring events Glyburide 
n=4374 
3115.5 person years of follow-
up 
Median (IQR) days of follow-
up, 79.5 (30 to 230) 
Gliclazide 
n=4374 
4355.2 person years of follow-
up 
Median (IQR) days of follow-
up, 150 (48 to 520) 
Hospital encounters with 
hypoglycemia 
  
Number of events 94 (2.2%) 20 (0.5%) 
Event rate per 1000 person   
years 
30.2 4.6 
Censoring events   
Death 7 (0.2%) 12 (0.3%) 
Study sulphonylurea 
discontinued 
3529 (80.7%) 3605 (82.4%) 
Prescription for a non-study 
oral hypoglycemic agent or 
insulin 
744 (17.0%) 737 (16.9%) 
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Table 6: Events in metformin combination study time to event analysis 
Censoring events Glyburide 
n=8038 
6973.4 person years of follow-
up 
Median (IQR) days of follow-
up, 90 (30 to 323) 
Gliclazide 
n=8038 
9101.6 person years of follow-
up 
Median (IQR) days of follow-
up, 192.5 (49 to 669) 
Hospital encounters with 
hypoglycemia 
  
Number of events 205 (2.6%) 41 (0.5%) 
Event rate per 1000 person 
years 
29.4 4.5 
Censoring events   
Death 11 (0.1%) 7 (0.1%) 
Study sulphonylurea 
discontinued 
6843 (85.1%) 6948 (86.4%) 
Prescription for non-study oral 
hypoglycemic agent or insulin 
979 (12.2%) 1042 (13.0%) 
 
  
 
 
 
 
 
 
 
  
93 
 
 
93 
Figure 1: Flow diagram representing monotherapy study inclusions and exclusions 
 
 
 
 
 
 
 
 
 
 
 Patients with an outpatient prescription for oral 
hypoglycemic agent between April 2002 and 
December 2011 
(n = 274,896) 
Patients included in study before 
matching (n = 18,804) 
Glyburide users: 13,550 
Gliclazide MR users: 5254  
Patients excluded from study (n = 256,092) 
 Age <66 at the time of oral hypoglycemic agent prescription:   
      12,756 
Evidence of insulin or oral hypoglycemic agent dispensed in 1 year 
prior to index date: 227,727 
Evidence of medication commonly associated with hypoglycemia in 
1 year prior to index date: 681 
Evidence of at least 1 hospital encounter with hypoglycemia in 5 
years prior to the index date: 543 
Evidence of end-stage renal disease in 5 years prior to the index 
date: 753 
Evidence of hospital discharge in the 2 days prior to or on index 
date: 2583 
Ineligible study dose: 11,049 
Patients included in study after matching 
(n = 8748) 
Glyburide users: 4374 
Gliclazide MR users: 4374  
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Figure 2: Flow diagram representing metformin combination study inclusions and 
exclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients with an outpatient prescription for oral 
hypoglycemic agent between April 2002 and 
December 2011 
(n = 274,969) 
Patients included in study before 
matching (n = 26,598) 
Glyburide users: 16,631 
Gliclazide MR users: 9967 
Patients excluded from study (n = 248,371) 
No evidence of one or more metformin prescription dispensed   
  on the index date or in the 180 days prior to the index date:    
  78,694  
Age <66 at the time of oral hypoglycemic agent prescription:  
  12,445 
Evidence of insulin or other oral hypoglycemic agent dispensed      
  in 1 year prior to index date (besides metformin): 145,139 
Evidence of medication commonly associated with  
  hypoglycemia in 1 year prior to index date: 706 
Evidence of at least 1 hospital encounter with hypoglycemia in 5  
  years prior to the index date: 522 
Evidence of end-stage renal disease in 5 years prior to the  
  prescription date: 217 
Evidence of hospital discharge in the 2 days prior to or the index  
  date: 2940 
Ineligible study dose: 7708 
Patients included in study after matching 
(n = 16,076) 
Glyburide users: 8038 
Gliclazide MR users: 8038 
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Appendix C  
Dataset Creation Plan for “The Hypoglycemic Risk of Glyburide 
Compared with Modified Release Gliclazide” 
 
Number of Study 2014 0906 038 000 
Contacts 
Jamie Fleet  
Amit Garg  
Stephanie Dixon  
Kristin Clemens  
 
PIA Approved? Yes 
DCP update history 
Version 0 – May 21st 2013 (JF) 
Version 1 – July 8th 2013 (JF after comments from AG and EM) 
Update History.doc
 
Version 2 – July 22nd 2013 (JF after meeting with KC, AG, EM) 
Version 3 – Aug 15, 2013 (KC after meeting with AG, EM) 
Version 4 – December 20, 2013 (KC) 
Version 5 – December 31, 2013 (KC after comments from AG) 
Version 6 – November 26th, 2014 (based on the recommendations of CJD) 
Short Description of Research Question 
Oral hypoglycemic agents are used to help control diabetes mellitus. We 
will explore the risk of a hospital encounter with hypoglycemia in new, 
older adult users of these medications – specifically in users of glyburide 
vs modified-release gliclazide. 
List of Datasets Used 
RPDB  
 
ODB   
Population 
 Age 65+ 
 
CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or ‘AT’) 
Diagnosis Type (dxtype) 
  All (alldx) 
 
OHIP 
Claim Type 
 Nonlab 
 
NACRS  
Source 
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 Emergency Department visits 
Include planned visits 
No 
Include suspected/questionable diagnoses? 
 No 
 
Gamma-Dynacare  
Type of test 
 Serum creatinine ‘/home/sdixon/data/GD/fullSCr’ 
 Hemoglobin A1C – test number 093D 
 Glucose serum fasting – test number 111G 
 Glucose serum random – test number 111H 
 
Cerner  
File name: /ices/CDP/cerner/cerner_apr99_dec10.sas7bdat 
Hospital Stay 
 Inpatient (Disposition = “Inpatient”) 
 Outpatient (Disposition = “Outpatient”) 
 Emergency Room (Disposition = “Emergency Room”) 
 
Type of test 
 Serum creatinine in µmol/L (Test_Done = “A”) 
 Serum glucose in mmol/L (Test_Done = “B”) 
 
Defining the Cohort 
Index Event Prescription for new sulphonylurea medication 
Inclusion – 
Cohorts A  
Patients with an outpatient prescription for a study oral hypoglycemic agent (OHA) from ODB 
from April 1st 2002 to Dec 31st 2011 in one of the following DCLASSes:, S_GLY, S_GLC,  
 
This date will be the OHA prescription date 
Exclusions – 
Cohorts A  
1. Data cleaning 
a. Invalid IKN 
b. Missing age/sex 
c. Non-Ontario resident (CIHI variable prdcddablk does not begin with “35”) 
d. Death on or before OHA prescription date 
2. Age <66 on OHA prescription date 
3. Evidence of any previous OHA in the 1 year prior (DCLASS: S_MET, S_GLY, 
S_GLC, S_GLM, S_REP, S_ROS, S_PIO, S_SIT, S_SAX, S_LIN, S_ACB, S_INS, 
S_MES) or more than 1 DCLASS type on the prescription date 
4. Evidence of the following drugs in the 1 year prior to prescription date that have been 
linked to hypoglycemia (DCLASS = EX) 
5. Evidence of hypoglycemia in ER or hospital in 5 years prior to prescription date 
 
CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or ‘AT’) 
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Diagnosis Type (dxtype) 
  All (alldx) 
 
NACRS  
Source 
 Emergency Department visits 
Include planned visits 
No 
Include suspected/questionable diagnoses? 
 No 
 
hypoglycemia.txt
 
6. Evidence of any dialysis in the 1 year prior, or renal transplant in the 5 years prior (one 
or more of the codes below) 
dialysis exclusion 
with pre 2002 codes.txt
renal transplant.txt
 
7. Evidence of hospital discharge up to 2 days prior to or on OHA prescription date 
8. Restrict to study doses as follows:  
Dose Gliclazide Modified 
Release 
Glyburide 
1 30mg 5mg 
2 60mg 10mg 
3 90g 15mg 
4 120mg 20mg 
Note: This also requires exclusion of gliclazide non-modified release: DCLASS = NS 
9. If more than one eligible prescription is available, restrict to first 
 
Inclusion – 
Cohorts B 
Patients with an outpatient prescription for a study oral hypoglycemic agent (OHA) from ODB 
from April 1st 2002 to Dec 31st 2011 in one of the following DCLASSes: S_GLY, S_GLC,  
This date will be the OHA prescription date 
Exclusions – 
Cohorts B 
1. Look back 180 days from OHA prescription date for at least 1 prescription for 
metformin (DCLASS = S_MET). This includes evidence of S_MET first prescribed on 
the index date.  Exclude if does not meet this criteria (i.e. exclude if no evidence of 
prior metformin use, either in the preceding days or co-prescribed with the oral 
hypoglycemic of interest on the index date)  
• See drug list in Appendix A 
• Note: The day supply of the most recent metformin prescription [i.e. the most 
recent metformin prescription prior to OHA prescription date] must cross the OHA 
prescription date (if co-prescribed on the same day then not an issue).  
2. Data cleaning 
a. Invalid IKN 
b. Missing age/sex 
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c. Non-Ontario resident (CIHI variable prdcddablk does not begin with “35”) 
d. Death on or before OHA prescription date 
3. Age <66 on OHA prescription date 
4. Evidence of any previous OHA other than metformin in the 1 year prior (DCLASS: 
S_GLY, S_GLC, S_GLM, S_REP, S_ROS, S_PIO, S_SIT, S_SAX, S_LIN, S_ACB, 
S_INS) or more than 1 DCLASS (except S_MET) type on the prescription date 
5. Evidence of the following drugs that have been linked to hypoglycemia (DCLASS = 
EX) 
6. Evidence of hypoglycemia in ER or hospital in 5 years prior to prescription date (see 
cohort A for codes) 
7. Evidence of any dialysis in the 1 year prior, or renal transplant in the 5 years prior (one 
or more of the codes in Cohort A and B exclusions) 
8. Evidence of hospital discharge up to 2 days prior to or on OHA prescription date 
10. Restrict to study doses as follows:  
Dose Gliclazide Modified 
Release 
Glyburide 
1 30mg 5mg 
2 60mg 10mg 
3 90g 15mg 
4 120mg 20mg 
Note: This also requires exclusion of gliclazide non-modified release: DCLASS = NS 
9. If more than one eligible prescription is available, restrict to first 
 
 
 Time Frame Definitions 
 
 
 
 
 
 
 
Accrual Start/End 
Dates 
April 1st 2002 to December 31st 2011  
Max Follow-up 
Date 
March 31st 2012 
When does the 
observation 
window 
terminate? 
1. 90 days after index 
2. Death 
3. Max follow-up (March 31, 2012) 
Lookback 
Window 
120 days for baseline medications 
5 years for comorbidities 
1 year for OHA’s 
1 year for labs 
Exposure New sulphonylurea prescription – glyburide vs modified-release gliclazide 
 
Observation Window 
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 Variable Definitions 
Outcome Definitions  NACRS  
Source 
 Emergency Department visits 
Include planned visits 
No 
Include suspected/questionable diagnoses? 
 No 
 
CIHI-DAD  
Source 
 Inpatient 
Institution types 
 Acute care (insttype = ‘AP’ or ‘AT’) 
 
Diagnosis Type (dxtype) 
  All (alldx) 
 
 
RPDB 
90 day outcomes 
below)  
1. Emergency room visit  or Hospitalization with hypoglycemia  
hypoglycemia.txt
 
2. All-cause mortality  
 
Propensity Score Definition See Appendix A (Drug list) and D for baseline codes, drug list and additional details 
• The propensity score is defined as the probability of exposure (E) 
conditional on the covariates (See variables below): Pr (E=1IX1, X2, 
X3, …, Xn) 
• We will obtain a propensity score per patient (in both the gliclazide 
and glyburide groups) by fitting a logistic model (proc logistic) that 
estimates the probability of an OHA prescription given the 
covariates below and extracting the predicted probabilities 
• Consider the following variables in the derivation of the propensity 
score using multivariable logistic regression model: 
 
Demographics 
Age at index year (per year) 
 
Sex (men or women; referent = women) 
 
Location of residence (urban or rural; referent = urban; include 
patients with ‘missing’ in the referent group for the purpose of 
developing propensity score) 
 
100 
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Socioeconomic status (neighbourhood income quintile) (quintiles 
1,2,3,4 or t; include patients with ‘missing’ in quintile 3 for the 
purpose of developing the propensity score) 
 
Residential status (community-dwelling or long-term care; 
referent=community dwelling) 
 
Charlson score (0, 1, 2, or ≥3; include patients with ‘missing’ as 
score of 0 for the purpose of developing the propensity score) 
 
Comorbidities 
Alcoholism (yes/no; referent=no) 
 
Chronic kidney disease (yes/no; referent=no) 
 
Chronic liver disease (yes/no; referent = no) 
 
Diabetic retinopathy (yes/no; referent=no) 
 
PVD (yes/no; referent=no) 
 
Heart failure (yes/no; referent=no) 
 
Sepsis (yes/no; referent=no) 
 
Pituitary disease (yes/no; referent=no) 
 
Adrenal issues (yes/no; referent=no) 
 
Thyroid disease (yes/no;referent=no) 
 
Pancreatitis (yes/no; referent=no) 
 
Cystic fibrosis (yes/no; referent = no) 
                           
                          Pancreatectomy (yes/no; referent=no) 
 
                          Pancreatic cancer (yes/no; referent=no) 
 
                          Diabetic neuropathy (yes/no; referent=no) 
   
                          Dementia (yes/no; referent = no) 
 
Health Care Utilization 
Nephrologist visit (0, 1, 2, ≥3; referent = no) 
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Cardiologist visit (0, 1, 2, ≥3; referent = no) 
 
Ophthalmologist visit (0, 1, 2, ≥3; referent = no) 
 
Endocrinologist visit (0, 1, 2, ≥3; referent = no) 
 
Internist visit (0, 1, 2, ≥3; referent = no) 
 
Carotid ultrasound (yes/no; referent=no) 
 
Coronary angiogram (yes/no; referent=no) 
 
Coronary revascularization (yes/no; referent=no) 
 
Echocardiography (yes/no; referent=no) 
 
Holter monitoring (yes/no; referent =no) 
 
Stress test (yes/no; referent = no) 
 
 
                          CABG (yes/no; referent=no) 
                           
Glycosylated hemoglobin (yes/no; referent=no) 
 
Diabetes management (yes/no; referent = no) 
 
Diabetes incentive (yes/no; referent=no) 
 
Diabetes management by a specialist (yes/no; referent = no) 
 
Diabetes management by a specialist team (yes/no; referent=no) 
 
Prescribed Medication use (120 day look-back) 
Acetohexamide (yes/no; referent=no) 
 
ACE inhibitors (yes/no; referent=no) 
 
ARBs (yes/no; referent=no) 
 
Aliskiren (yes/no; referent=no) 
 
Beta blockers (yes/no;referent=no) 
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Ezetimibe (yes/no; referent=no) 
 
Fibrates (yes/no; referent = no) 
 
Glucose test strips (yes/no; referent = no) 
 
Loop diuretics (yes/no; referent = no) 
 
Potassium sparing diuretics (yes/no; referent = no) 
 
Statins (yes/no; referent = no) 
 
Thiazide diuretics (yes/no; referent = no) 
 
Gatifloxacin/Levofloxacin (yes/no; referent = no) 
 
Pentamidine (yes/no; referent = no) 
 
Quinine (yes/no; referent = no) 
 
Indomethacin (yes/no; referent = no) 
 
Tacrolimus/sirolimus (yes/no; referent=no) 
 
Clonidine (yes/no; referent = no) 
 
Chloramphenicol (yes/no; referent = no) 
 
H2 Receptor Antagonist (yes/no; referent = no) 
 
Clarithromycin (yes/no; referent = no) 
 
Cyclosporine (yes/no; referent=no) 
 
Fluconazole/voriconazole/miconazole (yes/no;referent =no) 
 
Pegvisimont (yes/no; referent=no) 
 
Probenecid (yes/no; referent=no) 
 
Rifampin (yes/no; referent =no) 
 
Amiodarone (yes/no; referent = no) 
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Valproic acid (yes/no; referent=no) 
 
Aprepitant (yes/no; referent=no) 
 
Bosentan (yes/no; referent = no) 
 
Carbamazepine (yes/no; referent = no) 
 
Antidepressants (yes/no; referent = no) 
 
Protease inhibitors (yes/no; referent = no) 
 
Atypical antipsychotics (yes/no; referent = no) 
 
Corticosteroids (yes/no; referent = no) 
 
Sulfonamide (yes/no; referent = no) 
 
MAOI inhibitor (yes/no; referent = no) 
 
Barbiturate (yes/no; referent = no) 
 
Tetracycline (yes/no;referent = no) 
 
Danazol (yes/no; referent = no) 
 
Thyroid replacement (yes/no; referent =no) 
 
Androgen (yes/no; referent = no) 
 
Disopyramine (yes/no; referent = no) 
 
Guanethidine (yes/no; referent = no) 
 
Ifosfamide (yes/no; referent = no) 
 
Phenylbutazone (yes/no; referent = no) 
 
Diazoxide (yes/no; referent = no) 
 
Isoniazid (yes/no; referent = no) 
 
Colesevelam (yes/no; referent = no) 
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Reserpine (yes/no; referent = no) 
 
Laboratory Testing (baseline characteristic only - not to be 
included in the propensity score): 
For Cohorts A and B (both pre and post matching), where available, 
provide: 
-Number (%) with creatinine in the 1 year prior 
-Mean (SD) creatinine 
-Median (IQR) creatinine 
-Mean (SD) eGFR 
-Median (IQR) eGFR 
-Number (%) with hemoglobin A1c in the 1 year prior 
-Mean (SD) hemoglobin A1c 
-Median (IQR) hemoglobin A1c 
 
 
Hard and Propensity Score 
Matching 
• We will use greedy matching with specified caliper width of 
(plus/minus) 0.6 x the standard deviation of the logit of the 
propensity score 
• The difference in the logit of the propensity score between the 
gliclazide and the glyburide groups in the matched set is required to 
be less than the pre-specified maximum caliper wide 
• We will match without replacement.  Matching gliclazide patients 
can no longer serve as a candidate for being matched to another 
glyburide patient 
 
Matching Ratio: We will match 1 gliclazide patient with 1 glyburide patient on: 
• The logit of the propensity score 
• Age at the index date (plus/minus 2 years) 
• Sex (men or women; referent=women) 
• CKD status (yes/no; referent = no) 
• Medication dose 
• At least 1 endocrinologist visit 
 
Dose Gliclazide Modified 
Release 
Glyburide 
1 30mg 5mg 
2 60mg 10mg 
3 90g 15mg 
4 120mg 20mg 
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Outline of Analysis Plan 
 
 
1. Cohort Creation 
• Show prescriptions and unique IKNs that are included at each stage  
• Table 1A – Cohort A creation 
• Table 1B – Cohort B creation  
2. Aggregate Event Rate 
• Show total number of patients, and broken down by CKD and no-CKD by codes  
• Show number and proportion of patients with events in each category 
• Table 2A – Cohort A  
• Table 2B – Cohort B  
3. Prescription Breakdown 
• Show number with each prescription type 
• Show min, max, median, IQR average daily dose for each prescription  
• Table 3A – Cohort A 
• Table 3B – Cohort B  
• Note: For cohort B show how many prescriptions for metformin in 120 days prior to 
OHA prescription date (min # prescriptions, max # prescriptions, median # prescriptions, 
25th percentile # of prescriptions, 75th percentile # of prescriptions). See Table 3D, 3E, 
3F 
4. Continuous Usage  
• Show only for patients who have at least one year of prescriptions (those accrued no 
later than March 31st 2011; have done this to allow for the possibility of at least one full 
year of follow-up data) 
• Look forward to end of day supply for last eligible prescription to assess continuous 
usage in number of days.  
• If index script is the only prescription, look to the end of its day supply.  
• Eligible prescriptions are those in the same DCLASS and with a subsequent 
prescription a max of 10 days following the end of day supply of the previous prescription 
(ie. could be before 10 days for next prescription) 
• Person is no longer the continuous user if: 
o No more evidence of the DCLASS 10 days after end of prior prescription day supply 
o switch to a different DCLASS 
o die 
o end of follow up (March 31st 2012) 
 
5. Metformin Usage After Index – Cohort A and B 
• Show number of patients with ≥1 S_MET prescription within 180 days following the 
index date (not including the index date) 
 
6. Baseline characteristics 
• Show number and proportion with standardized differences comparing S_GLY and 
S_GLC for each characteristic listed in Appendix D 
• Look back 5 years for comorbidities, 1 year for lab values (where available), and 120 
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days for medications unless otherwise specified 
• Table 6a is for COHORT A prior to matching and includes laboratory values 
• Table 6c is for COHORT A post-matching and includes laboratory values 
• Table 6b is for COHORT B prior to matching and includes laboratory values 
• Table 6d is for COHORT B post-matching and includes laboratory values 
 
7. Primary Analysis 
• Conditional logistic regression model looking at S_GLY vs. S_GLC with a 90 day 
follow up 
• Table 7 are for COHORT A – total cohort (all outcomes) 
• Table 8 are for COHORT B – metformin (all outcomes) 
9. Secondary analyses 
Costs of SU to ODB 
·Time to event analysis (censoring on death, receipt of non-study OHA, discontinuation of 
study  OHA) 
·Physician associated factors with prescription for glyburide from 2008-2011 (time since 
grad, origin of training, practice location 
·Characteristics of hypoglycemia episodes (time of day, number of ER’s/hospitals, number 
of prescribers) 
·Adjustment for year of cohort entry 
·Percentage with hypoglycemia by year 
·Baseline demographic characteristics of those with and without laboratory values (ie 
HbA1c and creatinine) available in the 1 year previous 
 
 
Appendices 
 
 
Appendix A: Drug List 
OHA drug list.xls OHA drug list extra 
BC.xls
 
 
Appendix B: Sample Tables 
OHA and 
hypoglycemia tables.xls
 
 
Appendix C: Cerner FSA Info 
CERNER Pharmacy 
FSA.xls
CERNER hospitals.xls
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Appendix D: Baseline Characteristics 
OHA and 
hypoglycemia baseline.txt
OHA new 
baselines.txt
 
 
Characteristic Datasets Used Other Details  
Age RPDB Mean, median, SD 
66-70 
71-75 
76-80 
81-85 
86-90 
>90 
Sex RPDB  
Income quintile PSTLYEAR (using %getdemo)  
Rural location PSTLYEAR (using %getdemo)  
Year of cohort entry (index date)   
LTC utilization ODB  
Charlson score  Measure of general 
comorbidity based on 
relative effects of a 
combination of diseases or 
risk factors on outcomes for 
a given individual to show 
expected mortality 
reported as 0, 1, 2, or ≥ 3; if 
there are no hospitalizations, 
code as 0 and not as 
‘missing’ 
Nephrologist visit in 1 year prior OHIP First, identify physicians 
who are Nephrologists: a 
physician who, during the 
study accrual period, had 
both: 
1) billed  ≥ 25 OHIP fee 
codes for “Nephrologist  
consult” (can be same 
patient, but have to be codes 
billed on separate days; i.e. 
no more than one OHIP 
A135 code per day)  
nephro codes.txt
 
 
AND 
2) billed ≥ 50 OHIP 
“dialysis” codes, with no 
more than 1 code on a given 
day (i.e. evidence of at least 
50 separate days of codes. 
108 
 
 
108
Note: some forms of acute 
dialysis were excluded from 
this dialysis list as this can 
be billed by a physician 
other than nephrologist i.e. 
intensive care physicians or 
during continuous veno-
venous hemodialysis) 
ohip dialysis codes 
for nephro consult .txt
 
Second, look for evidence of 
any of the “Nephrologist 
consult” OHIP Feecodes 
billed by a nephrologist in 
the past 1 year prior to 
index date 
Cardiologist visit IPDB Number of patients who 
have seen a cardiologist at 
least once in 1 year prior. 
Defined by mainspecialty = 
“CARDIOLOGY” 
Ophthalmologist visit  IPDB Number of patients who 
have seen a cardiologist at 
least once in 1 year prior. 
Defined by mainspecialty = 
“OPHTHALMOLOGY” 
Endocrinologist visit IPDB Number of patients who 
have seen a cardiologist at 
least once in 1 year prior. 
Defined by mainspecialty = 
“ENDOCRINOLOGY” 
Internist visit  IPDB Number of patients who 
have seen a cardiologist at 
least once in 1 year prior. 
Defined by mainspecialty = 
“INTERNAL MEDICINE” 
Prescribing physician main specialty IPDB NEPHROLOGY 
CARDIOLOGY 
OPHTHALMOLOGY 
ENDOCRINOLOGY 
INTERNAL MEDICINE 
GP/FP 
Missing 
Other  
Alcoholism CIHI-DAD 
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
Chronic kidney disease CIHI-DAD  
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Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
Chronic liver disease CIHI-DAD 
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
 
Carotid ultrasound CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
 
Coronary angiogram CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
 
Coronary revascularization CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
 
Echocardiography CIHI-DAD  
Source 
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 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
Holter monitoring CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
 
Stress test  CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
 
Glycosylated hemoglobin OHIP  
Claim Type 
 ALL 
 
Diabetic retinopathy CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
 
Diabetes management  OHIP  
Claim Type 
 NONLAB 
Look in 1 year prior 
 
(FYI – this is for GP) 
Diabetes incentive OHIP  
Claim Type 
 NONLAB 
Look in 1 year prior 
Diabetes management by a specialist OHIP  
Claim Type 
 NONLAB 
Look in 1 year prior 
 
(FYI – specialists can include 
internists, endocrinologists, or 
pediatricians) 
Diabetes management by a specialist 
team 
OHIP  
Claim Type 
Look in 1 year prior  
 
(FYI – specialists in this case 
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 NONLAB can mean internists or 
endocrinologists) 
 
Also show diabetes 
management by a specialist OR 
team in 1 year prior  
PVD CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
 
Heart failure CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
 
CABG CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
 
Sepsis CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
 
Pituitary issues CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
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diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
Adrenal issues CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
 
Thyroid issues CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
OHIP  
Claim Type 
 NONLAB 
 
Pancreatitis CIHI-DAD 
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
Cystic fibrosis CIHI-DAD 
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
Pancreatectomy CIHI-DAD 
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
Pancreatic Cancer CIHI-DAD 
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
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‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
  
 
  
 
Lab values if available 
Fasting serum glucose Gamma Dynacare 
 Glucose serum fasting – test 
number 111G 
Please provide mean, SD, 
median, IQR 
 
Serum glucose (random) Gamma Dynacare 
 Glucose serum random – test 
number 111H 
Please provide mean, SD, 
median, IQR 
 
HbA1C Gamma Dynacare 
 Hemoglobin A1C – test number 
093D 
Range of acceptable values for 
HbA1C include 1 to 25%. 
Values <1% and >25% will be 
excluded. Values that do not lie 
in the specified range are likely 
errors.  
 
Please provide mean, SD, 
median, IQR 
 
Serum creatinine Gamma Dynacare  
Type of test 
 Serum Creatinine  
 ‘/home/sdixon/data/GD/fullSCr’ 
CERNER 
Type of test 
 Serum creatinine in µmol/L 
(Test_Done = “A”) 
Hospital Stay 
 Inpatient (Disposition = 
“Inpatient”) 
 Emergency Room (Disposition = 
“Emergency Room”) 
 Outpatient (Disposition = 
“Outpatient”)  
 
Range of acceptable values for 
serum creatinine include 10-
2500 µmol/L. Values <10 
µmol/L and >2500 µmol/L will 
be excluded. Values that do not 
lie in the specified range are 
likely errors. 
Please provide mean, SD, 
median, IQR 
GFR Gamma Dynacare  
Type of test 
 Serum Creatinine - variable: 
“ckd_epi_egfr”   
Serum creatinine 
(main_gd_dec10tojan11_sent_mar11, 
[main_gd_jan02tonov10_sent_dec10) 
CERNER 
Type of test 
 Serum creatinine in µmol/L 
(Test_Done = “A”) 
Hospital Stay  
 Inpatient (Disposition = 
“Inpatient”) 
 Emergency Room (Disposition = 
“Emergency Room”) 
 Outpatient (Disposition = 
“Outpatient”)  
o For CERNER, use CKD-
EPI equation 
=141 x min([serum creatinine in 
umol/L /88.4 ]/κ, 1)α  x 
max([serum creatinine in 
umol/L / 88.4]/κ, 1)-1.209 x 
0.993Age x 1.018 [if Female] x 
1.159 [if African American] 
 
κ=0.7 for females and 0.9 for 
males,  
α= -0.329 for females and -
0.411 for males,  
min=the minimum of Scr/κ or 1,  
max=the maximum of Scr/κ or 
1. 
 
Please provide mean, SD, 
median, IQR 
 
Also put into the following 
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categories:  
eGFR >60 
45-59 
30-44 
15-29 
<15 mL/min/1.73m2 
 
 
Medication DCLASS 
Acetohexamide  BC_ACT 
ACE inhibitors BC_ACE 
ARBs BC_ARB 
Aliskiren BC_ALI 
Beta blockers BC_BBL 
Ezetimibe BC_EZE 
Fibrates BC_FIB 
Glucose test strips BC_STR 
Loop diuretics BC_LOP 
Potassium sparing diuretics BC_KSD 
Statins BC_STA 
Thiazide diuretics BC_TZD 
Gatifloxacin/Levofloxacin BC_GAT 
Pentamidine BC_PEN 
Quinine BC_QUI 
Indomethacin BC_IND 
Tacrolimus/sirolimus BC_LIM 
Clonidine BC_CLO 
Chloramphenicol BC_CHL 
H2 receptor antagonists BC_HRA 
Clarithromycin BC_CLA 
Cyclosporine BC_CYC 
Fluconazole/voriconazole/miconazole BC_FLV 
Pegvisomant BC_PEG 
Probenecid BC_PBD 
Rifampin BC_RIF 
Amiodarone BC_AMI 
Valproic acid BC_VAL 
Aprepitant BC_APR 
Bosentan BC_BOS 
Carbamazepine BC_CAR 
Antidepressants BC_DEP 
Protease inhibitors BC_PRO 
Atypical antipsychotics BC_APS 
Corticosteroids BC_CCS 
Sulfonamides BC_SUL 
MAOI Inhibitors BC_MAO 
Barbiturates BC_BAR 
Tetracycline BC_TET 
Danazol BC_DAN 
Thyroid hormone BC_THY 
Androgens BC_TES 
Disopyramine BC_DIS 
Guanethidine BC_GUA 
Ifosfamide BC_IFO 
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Phenylbutazone BC_PHE 
Diazoxide BC_DIA 
Isoniazid BC_ISO 
Colesevelam BC_COL 
Reserpine BC_RES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
116 
 
 
116
Appendix D  
Supplementary Materials for “Trends in Antihyperglycemic Medication 
Prescriptions in Older Adults: 2002-2013” 
 
Table 1. Checklist of recommendations for reporting of observational studies using the 
STROBE guidelines 
Table 2. Coding definitions for demographic and comorbid conditions 
Table 3. Coding definitions for hospital presentation with hypoglycemia 
Table 4. Baseline characteristics of patients with newly treated diabetes 
Table 5. Timeline of safety events during study period – thiazolidinediones 
Figure 1. Mono and combination therapy 2002-2013 
Figure 2. Insulin mono/combination therapy 2002-2013 
Figure 3. Oral antihyperglycemic medication prescriptions in insulin combination therapy 
users 2002-2013 
Figure 4. Antihyperglycemic medication prescriptions in patients with newly treated 
diabetes 2002-2013 
Figure 5. Mono/combination therapy in patients with newly treated diabetes 2002-2013 
Figure 6. Insulin mono and combination therapy in patients with newly treated diabetes 
2002-2013  
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Table 1. Checklist of recommendations for reporting of observational studies using 
the STROBE guidelines 
 
 Item 
No Recommendation Reported 
 Title and abstract 1 
(a) Indicate the study’s design with a commonly 
used term in the title or the abstract Abstract 
(b) Provide in the abstract an informative and 
balanced summary of what was done and what was 
found 
Abstract 
Introduction 
 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported Introduction 
Objectives 3 State specific objectives, including any pre-
specified hypotheses Introduction 
Methods 
 
Study design 4 Present key elements of study design early in the paper Methods 
Setting 5 
Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-
up, and data collection 
Methods 
Participants 6 
(a) Give the eligibility criteria, and the sources and 
methods of selection of participants. Describe 
methods of follow-up 
Methods 
(b) For matched studies, give matching criteria and 
number of exposed and unexposed Not applicable 
Variables 7 
Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable 
Methods and 
Appendix D 
Table 2 and 3 
Data sources/ 
measurement 8 
For each variable of interest, give sources of data 
and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than one group 
Methods and 
Appendix D 
Table 2 and 3 
Bias 9 Describe any efforts to address potential sources of bias Methods 
Study size 10 Explain how the study size was arrived at Not applicable 
Quantitative 
variables 11 
Explain how quantitative variables were handled in 
the analyses. If applicable, describe which 
groupings were chosen and why 
Methods 
Statistical methods 12 
(a) Describe all statistical methods, including those 
used to control for confounding Methods 
(b) Describe any methods used to examine Methods 
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subgroups and interactions 
(c) Explain how missing data were addressed Not applicable 
(d) If applicable, explain how loss to follow-up was 
addressed Not applicable 
(e) Describe any sensitivity analyses Not applicable 
Results 
 
Participants 13 
(a) Report numbers of individuals at each stage of 
study—e.g. numbers potentially eligible, examined 
for eligibility, confirmed eligible, included in the 
study, completing follow-up, and analyzed 
Results 
(b) Give reasons for non-participation at each stage Results 
(c) Consider use of a flow diagram  
Descriptive data 14 
(a) Give characteristics of study participants (e.g. 
demographic, clinical, social) and information on 
exposures and potential confounders 
Results, Table 
7, and Appendix 
D Table 4 
(b) Indicate number of participants with missing 
data for each variable of interest Not applicable 
(c) Summarize follow-up time (e.g. average and 
total amount) Not applicable 
Outcome data 15 Report numbers of outcome events or summary 
measures over time Results 
Main results 16 
(a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision 
(e.g. 95% confidence interval). Make clear which 
confounders were adjusted for and why they were 
included 
Results 
(b) Report category boundaries when continuous 
variables were categorized Results 
(c) If relevant, consider translating estimates of 
relative risk into absolute risk for a meaningful time 
period 
Not applicable 
Other analyses 17 Report other analyses done—e.g. analyses of 
subgroups and interactions, and sensitivity analyses Not applicable 
Discussion 
 
Key results 18 Summarize key results with reference to study 
objectives Discussion 
Limitations 19 
Discuss limitations of the study, taking into account 
sources of potential bias or imprecision. Discuss 
both direction and magnitude of any potential bias 
Discussion 
Interpretation 20 
Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence 
Discussion 
Generalizability 21 Discuss the generalizability (external validity) of the study results Discussion 
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Other information 
 
Funding 22 
Give the source of funding and the role of the 
funders for the present study and, if applicable, for 
the original study on which the present article is 
based 
Financial 
Disclosures 
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Table 2. Coding definitions for demographic and comorbid conditions 
 
Characteristics/ 
Condition Database Codes 
Age RPDB  
Sex RPDB  
Income quintile Statistics 
Canada 
 
Rural location Statistics 
Canada 
 
Chronic kidney 
disease 
CIHI-
DAD 
OHIP 
ICD 9: "4030", "4031", "4039", "4040", "4041", "4049", 
"585", "586", "5888", "5889", "2504" 
 
ICD 10: "E102", "E112", "E132", "E142", "I12", "I13", 
"N08", "N18", "N19" 
 
OHIP DX: "403", "585" 
Chronic liver 
disease 
CIHI-
DAD 
OHIP 
ICD 9: "4561", "4562", "070", "5722", "5723", "5724", 
"5728", "573", "7824", "V026", "2750", "2751", "7891", 
"7895", "571" 
 
ICD 10: "B16", "B17", "B18", "B19", "I85", "R17", 
"R18", "R160", "R162", "B942", "Z225",  "E831", 
"E830", "K70", "K713", "K714", "K715", "K717", 
"K721", "K729", "K73", "K74", "K753", "K754", 
"K758", "K759", "K76", "K77" 
 
OHIP DX: "571", "573", "070" 
 
OHIP FEE: "Z551", "Z554" 
Any cancer CIHI 
OHIP 
ICD 9: "V10", "140", "141", "142", "143", "144", "145", 
"146", "147", "148", "149", "150", "151", "152", "153", 
"154", "155", "156", "157", "158", "159", "160", "161", 
"162", "163", "164", "165", "170", "171", "172", "173", 
"174", "175", "176", "179", "180", "181", "182", "183", 
"184", "185", "186", "187", "188", "189", "190", "191", 
"192", "193", "194", "1950", "1951", "1952", "1953", 
"1954", "1955", "1958", "196", "197", "198", "1990", 
"1991", "2000", "2001", "2002", "2008", "2010", "2011", 
"2012", "2014", "2015", "2016", "2017", "2019", "2020", 
"2026", "2028", "2029", "203", "204", "205", "206", 
"207", "208", "230", "231", "232",  "233", "234" 
 
ICD 10: "80003", "80006", "80013", "80023", "80033", 
"80043", "80102", "80103", "80106", "80113", "80123", 
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"80203", "80213", "83123", "87202", "87203", "959", 
"965", "966", "967", "968", "969", "970", "971", "980", 
"982", "984", "985", "986", "987", "988", "989", "990", 
"991", "993", "C00", "C01", "C02", "C03", "C04", 
"C05", "C06", "C07", "C08", "C09", "C10", "C11", 
"C12", "C13", "C14", "C15", "C16", "C17 C18", "C19", 
"C20", "C21", "C22", "C23", "C24", "C25", "C26", 
"C30", "C31", "C32", "C33", "C34", "C37", "C38", 
"C39", "C40", "C41", "C43", "C44", "C45”, “C46", 
"C47", "C48", "C49", "C50", "C51", "C52", "C53", 
"C54", "C55", "C56", "C57", "C58", "C60", "C61", 
"C62", "C63", "C64", "C65", "C66", "C67", "C68", 
"C69", "C70", "C71", "C72", "C73", "C74", "C75" 
,"C76", "C77", "C78", "C79", "C80", "C81", "C82", 
"C83", "C84", "C85", "C90", "C91", "C92", "C93", 
"C94", "C95", "C96", "C97", "D00", "D01", "D02", 
"D03", "D04", "D05", "D06", "D07", "D09" 
 
OHIP DX: "140", "141", "142", "143", "144", "145", 
"146", "147", "148", "149", "150", "151", "152", "153", 
"154", "155", "156", "157", "158", "159", "160", "161", 
"162", "163 164"," 165", "170", "171", "172", "173", 
"174", "175", "179", "180", "181", "182", "183", "184", 
"185", "186", "187", "188", "189 190", "191", "192", 
"193", "194", "195", "196", "197", "198", "199", "200", 
"201", "202", "203", "204", "205", "206", "207", "208" 
Coronary artery 
disease 
(excluding 
angina) 
CIHI-
DAD 
OHIP 
 
ICD 9: "412", "410" 
 
ICD 10: "I21", "I22", "Z955", "T822" 
 
CCI: "1IJ50", "1IJ76" 
 
CCP: "4801", "4802", "4803", "4804", "4805", "481", 
"482", "483" 
 
OHIP FEE: "R741", "R742", "R743", "G298", "E646", 
"E651", "E652", "E654", "E655", "Z434", "Z448" 
 
OHIP DX: "410", "412" 
Congestive heart 
failure 
CIHI-
DAD 
OHIP 
ICD 9: "425", "5184", "514", "428" 
 
ICD 10: "I500", "I501", "I509", "I255", "J81" 
 
CCP: "4961", "4962", "4963", "4964" 
 
CCI: "1HP53", "1HP55", "1HZ53GRFR", 
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"1HZ53LAFR", "1HZ53SYFR" 
 
OHIP FEE: "R701", "R702", "Z429" 
 
OHIP DX: "428" 
Peripheral 
vascular disease 
CIHI-
DAD 
OHIP 
ICD 9: "4402", "4408", "4409", "5571", "4439", "444" 
 
ICD 10: "I700", "I702", "I708", "I709", "I731", "I738", 
"I739", "K551" 
 
CCP: "5125", "5129", "5014", "5016", "5018", "5028", 
"5038" 
 
CCI: "1KA76", "1KA50", "1KE76", "1KG26", 
"1KG50", "1KG57", "1KG76MI", "1KG87" 
 
OHIP FEE: "R787", "R780", "R797", "R804", "R809", 
"R875", "R815", "R936", "R783", "R784","R785", 
"E626", "R814", "R786", "R937", "R860", "R861", 
"R855", "R856", "R933", "R934", "R791", "E672", 
"R794", "R813", "R867", "E649" 
Dementia CIHI-
DAD 
OHIP 
ICD 9: "2900", "2901", "2903", "2904", "2908", "2909", 
"2948", "2949", "3310", "3311", "3312", "2941", "797" 
 
ICD 10: "F065", "F066", "F068", "F069", "F09", "F00", 
"F01", "F02", "F03", "F051", "G30", "G31", "R54" 
 
OHIP DX: "290","331", "797" 
Stroke/ 
Transient 
ischemic attack 
CIHI-
DAD 
 
 
 
 
 
ICD 9: "430", "431", "434", "435", "436" 
 
ICD 10: "I630", "I631", "I632", "I633", "I634", "I635", 
"I638", "I639", "I64", "H341", "I600", "I601", "I602", 
"I603", "I604", "I605", "I606", "I607", "I609", "I61", 
"G450", "G451", "G452", "G453", "G458", "G459" 
Neuropathy CIHI-
DAD 
 
ICD 9: "3572" 
 
ICD 10: “E1040”,”E10400”, 
“E10401”,”E10402”,“E10403”, “E10404”, “E10409”, 
“E1041”, “E10410”, “E10411”, “E10412”, 
“E10413”, “E10414”, “E10419”, “E1042”, “E10420”, 
“E10421”, “E10422”, 
“E10423”,“E10424”,“E10429”,“E10480”,“E10481”,“E1
0482”, “E10483”,“E10484”, “E10489”, “E10490”, 
“E10491”, “E10492”, “E10493”, “E10494”, “E10499”, 
“E1140”, “E11400”, “E11401”, “E11402”, “E11403”, 
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“E11404”, “E11409”, “E1141”, “E11410”, “E11411”, 
“E11412”, “E11413”, “E11414”, “E11419”, “E1142”, 
“E11420”, “E11421”, “E11422”, “E11423”, “E11424”, 
“E11429”, “E11480”, “E1148”, “E11482”, “E11483”, 
“E11484”, “E11489”, “E11490”, “E11491”, “E11492”, 
“E11493”, “E11494”, “E11499”, “E1340”, “E13400”, 
“E13401”, “E13402”, “E13403”, “E13404”, “E13409”, 
“E1341”, “E13410”, “E13411”, “E13412”, “E13413”, 
“E13414”, “E13419”, “E1342”, “E13420”, “E13421”, 
“E13422”, “E13423”, “E13424”, “E13429”, “E13480”, 
“E13481”, “E13482”, “E13483”, “E13484”, “E13489”, 
“E13490”, “E13491”, “E13492”, “E13493”, “E13494”, “ 
“E13499”, “E1440”, “E14400”, “E14401”, “E14402”, 
“E14403”, “E14404”, “E14409”, “E1441”, “E14410”, 
“E14411”, “E14412”, “E14413”, “E14414”, “E14419”, 
“E1442”, “E14420”, “E14421”, “E14422”, “E14423”, 
“E14424”, “E14429”, “E14480”, “E14481”, “E14482”, 
“E14483”, “E14484”, “E14489”, “E14490”, “E14491”, 
“E14492”, “E14493”, “E14494”, “E14499”, “G590”, 
“G632” 
Retinopathy CIHI-
DAD 
 
 
ICD 9: “36201”, “36202”, “36210”, “36212”, “36229” 
  
ICD 10: “E1030”, “E10300”, “E10301”, “E10302”, 
“E10303”, “E10304”, “E10309”, “E1031”, “E10310”, 
“E10311”, “E10312”, “E10313”, “E10314”, “E10319”, 
“E1032”, “E10320”, “E10321”, “E10322”, “E10323”, 
“E10324”, “E10329”, “E1033”, “E10330”, “E10331”, 
“E10332”, “E10333”, “E10334”, “E10339”, “E10340”, 
“E10341”, “E10342”, “E10343”, “E10344”, “E10349”, 
“E1130”, “E11300”, “E11301”, “E11302”, “E11303”, 
“E11304”, “E11309”, “E1131”, “E11310”, “E11311”, 
“E11312”, “E11313”, “E11314”, “E11319”, “E1132”, 
“E11320”, “E11321”, “E11322”, “E11323”, “E11324”, 
“E11329”, “E1133”, “E11330”, “E11331”, “E11332”, 
“E11333”, “E11334”, “E11339”, “E11340”, “E11341”, 
“E11342”, “E11343”, “E11344”, “E11349”, “H360” 
Number of 
cholesterol tests 
OHIP OHIP FEE: “L055” 
Number of 
HbA1c tests 
OHIP OHIP FEE: “L093" 
Number of 
creatinine tests 
OHIP OHIP FEE: OHIP FEE: "L065", "L067", "L068" 
Number of 
glucose tests 
OHIP OHIP FEE: "L111" 
Major eye 
examination 
OHIP OHIP FEE: "A112", "A233", "A234", "A235", "A236", 
A239", "V401", "V406", "V402" 
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Abbreviations: CIHI, Canadian Institute for Health Information’s Discharge Abstract 
Database; CCI, Canadian Classification of Health Interventions; CCP, Canadian 
Classification of Diagnostic, Therapeutic, and Surgical Procedures; HbA1c, hemoglobin 
A1c; ICD 9, International Classification of Diseases 9th Revision; ICD 10, International 
Classification of Diseases 10th Revision; OHIP, Ontario Health Insurance Plan; RPDB, 
Registered Persons Database of Ontario 
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Table 3. Coding definitions for hospital presentation with hypoglycemia  
 
Condition Database Codes 
Hypoglycemia  CIHI-DAD NACRS 
ICD 10: E15, E160, E161, 
E162, E1063, E1163, 
E1363, E1463 
 
Abbreviations: CIHI, Canadian Institute for Health Information Discharge Abstract 
Database; ICD 10, International Classification of Diseases 10th Revision; NACRS, 
National Ambulatory Care Reporting System Database 
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Table 4. Baseline characteristics of patients with newly treated diabetes 
 April 1, 2002 April 1, 2007 April 1, 2012 
  N=3,498 % N=5,863 % N=4,478 % 
Age (yr) 
            
Mean (SD) 74.22 (6.24)   
74.45 
(6.43)   74.31 (6.63)   
Median (IQR) 73 (69-78)   
73 (69-
78)   73 (69-79)   
66-69 926 26.47% 1599 27.27% 1314 29.34% 
70-74 1083 30.96% 1661 28.33% 1275 28.47% 
75-79 801 22.90% 1337 22.80% 911 20.34% 
80-84 416 11.89% 780 13.30% 570 12.73% 
85-89 200 5.72% 355 6.05% 297 6.63% 
90+ 72 2.06% 131 2.23% 111 2.48% 
Sex - Female 1686 48.20% 2765 47.16% 2125 47.45% 
Income 
quintile             
Missing 9 0.26% 24 0.41% 8 0.18% 
1 (lowest) 797 22.78% 1238 21.12% 882 19.70% 
2 834 23.84% 1261 21.51% 947 21.15% 
3 679 19.41% 1110 18.93% 923 20.61% 
4 625 17.87% 1118 19.07% 901 20.12% 
5 (highest) 554 15.84% 1112 18.97% 817 18.24% 
Rural  
            
Missing ≤5 --- ≤5 --- ≤5 --- 
No 2955 84.48% 5146 87.77% 3890 86.87% 
Yes 542 15.49% 715 12.20% 587 13.11% 
Comorbiditiesa 
            
Chronic 
kidney disease 167 4.77% 575 9.81% 396 8.84% 
Chronic liver 
disease 130 3.72% 236 4.03% 170 3.80% 
Any cancer 920 26.30% 1508 25.72% 1153 25.75% 
Coronary 
artery disease 
(excluding 
cancer) 1136 32.48% 1,832 31.25% 1202 26.84% 
Congestive 
heart failure 559 15.98% 800 13.64% 513 11.46% 
Peripheral 
vascular 
disease 100 2.86% 129 2.20% 55 1.23% 
127 
 
 
127
Dementia 271 7.75% 488 8.32% 444 9.92% 
Stroke/TIA 139 3.97% 185 3.16% 135 3.01% 
Neuropathy ≤5 --- 21 0.36% 29 0.65% 
Retinopathy 13 0.37% 44 0.75% 17 0.38% 
Investigationsb 
      
Mean (SD) 
number 
cholesterol 
tests 
 0.96 (1.15) --- 
1.19 
(1.19) --- 1.11 (1.07) --- 
Median (IQR) 
cholesterol 
tests 1 (0-1) --- 1 (0-2) --- 1 (0-2) --- 
Mean (SD) 
HbA1c tests 1.25 (1.50) --- 
1.49 
(1.62) --- 1.45 (1.35) --- 
Median (IQR) 
HbA1c tests 1 (0-2) --- 1 (0-2) --- 1 (0-2) --- 
Mean (SD) 
creatinine tests 1.48 (1.91) --- 
1.84 
(2.14) --- 1.76 (1.91) --- 
Median (IQR) 
creatinine tests 1 (0-2) --- 1 (1-2) --- 1 (1-2) --- 
Mean (SD) 
glucose tests 2.03 (2.44) --- 
1.92 
(2.04) --- 1.62 (1.59) --- 
Median (IQR) 
glucose tests 1 (0-3) --- 2 (1-3) --- 1 (0-2) --- 
At least 1 eye 
exam 1,113  31.82% 1,887 32.18% 1,127  25.17% 
Laboratory 
Datac       
At least 1 
HbA1c 
outpatient lab 
value --- --- 1,235 21.06% 994 22.20% 
Mean (SD) 
HbA1c (%) --- --- 
6.8% 
(1.1%) --- 7.2% (1.2%) --- 
Mean (SD) 
HbA1c 
(mmol/mol)   51 (12)  55 (13.1)  
Median (IQR) 
HbA1c 
--- --- 
6.6% 
(6.1%-
7.2%) --- 
6.9% (6.5%-
7.5%) --- 
Median (IQR) 
HbA1c 
(mmol/mol)   
49 (43-
55)  52 (48-58)  
128 
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Abbreviations: TIA transient ischemic attack, SD standard deviation, IQR interquartile 
range, HbA1c glycosylated hemoglobin 
For reasons of privacy, cell sizes less than 6 are not presented. 
aComorbidities were examined in the 5 years prior. 
bInvestigations were examined in the 1 year prior. 
cLab values were available in the 1 year prior. 
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Table 5. Timeline of safety events during the study period– thiazolidinediones 
October 
2006 
Pioglitazone added to the province’s general benefit drug formulary 
January 
2007 
Rosiglitazone added to the province’s general benefit drug formulary 
February 
2007 
Safety signals emerge re: fracture risk with rosiglitazone 1 
 
May 2007 Regulatory warnings re: cardiac safety of rosiglitazone 2,3 
 
 
June 2007 Meta-analysis on cardiac safety of rosiglitazone published in the New 
England Journal of Medicine 4 
Nov 2007 Black box warning issued for rosiglitazone in the United States 5 
 
June 2009 Funding status for thiazolidinediones changed from General Benefit to the 
Exceptional Access Program in Ontario 6  
 
Sept 2010 Prescribing restrictions on thiazolidinediones placed in the United States 7 
 
June 2011 Regulatory attention to risk of bladder cancer with pioglitazone therapy 8 
 
1. Health Canada. Important safety information on rosiglitazone-containing products: 
AVANDIA®, AVANDAMET® and AVANDARYL™ [Internet]. 2007. 
http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2007/13994a-eng.php, 
Accessed Jan 30, 2015. 
2. Health Canada. Cardiac Safety of Avandia (rosiglitazone maleate) - For Health 
Professionals [Internet]. 2007. http://www.healthycanadians.gc.ca/recall-alert-rappel-
avis/hc-sc/2007/14440a-eng.php, Accessed Jan 30, 2015 
3.US Food and Drug Administration. Information for Healthcare Professionals 
Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl) [Internet]. 
http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationfor 
PatientsandProviders/ucm143460.htm, Accessed Jan 30, 2015 
4. Nissen SE, Wolski K.  Effect of rosiglitazone on the risk of myocardial infarction and 
death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71. 
5.US Food and Drug Administration. FDA Adds Boxed Warning for Heart-related Risks 
to Anti-diabetes Drug Avandia [Internet]. 2007. http://www.fda.gov/NewsEvents/ 
Newsroom/ PressAnnouncements/2007/ucm109026.htm, Accessed Jan 30, 2015. 
6.Ontario Ministry of Health and Long-term Care.  Change in Funding Status 
Rosiglitazone and Pioglitazone [Internet]. 2009. http://www.health.gov.on.ca/en/pro/ 
programs/drugs/opdp_eo/notices/notices_docs/tzd_faq.pdf, Accessed Jan 30, 2015. 
7.US Food and drug Administration. FDA significantly restricts access to the diabetes 
drug Avandia [Internet]. 2010. http://www.fda.gov/ Drugs/DrugSafety/Postmarket 
DrugSafetyInformationforPatientsandProviders/ucm226956.htm, Accessed Jan 30, 2015. 
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8. Health Canada. Health Canada reviewing diabetes drug pioglitazone (Actos) and 
potential risk of bladder cancer [Internet].  http://www.healthycanadians.gc.ca/recall-
alert-rappel-avis/hc-sc/2011/13617a-eng.php, Accessed 30 Jan 2015. 
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Figure 1. Mono and combination therapy 2002-2013 
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Figure 2. Insulin mono and combination therapy 2002-2013 
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Figure 3. Oral antihyperglycemic medication prescriptions in insulin combination 
therapy users 2002-2013 
 
*Drugs prescribed to less than 5% not illustrated (acarbose, acetohexamide, 
chlorpropamide, glimepiride, nateglinide, repaglinide, tolbutamide) 
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Figure 4. Antihyperglycemic medication prescriptions in patients with newly treated 
diabetes 2002-2013 
 
*Drugs prescribed to less than 5% not illustrated (acarbose, acetohexamide, 
chlorpropamide, glimepiride, nateglinide, repaglinide, tolbutamide) 
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Figure 5. Mono and combination therapy in patients with newly treated diabetes 
2002-2013 
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Figure 6. Insulin mono/combination therapy in patients with newly treated diabetes 
2002-2013 
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Appendix E  
Dataset Creation Plan for “Trends in Antihyperglycemic 
Medication Prescriptions and Hypoglycemia in Older Adults: 
2002-2013” 
 
TRIM Number of Study  
Research Program KDT 
Study Team (including 
contact information) 
Kristin Clemens  
Amit Garg  
Salimah Shariff  
Kuan Liu  
Eric McArthur  
Who will be responsible 
for DCP updates? KC 
PIA Approved? Yes 
DCP update history 
Version 1 KC (July 21, 2014) 
Version 2 KC (July 29th, 2014 after meeting with S.S.) 
Version 3 KC (September 14th, 2014 after meeting with IH, SS and KL) 
Version 4 KC (October 16 2014 after feedback from faculty scholars session and 
meeting with AG, SS, KL) 
 
Trends DCP 
Updates.docx
 
Short Description of 
Research Question 
Hypoglycemia is one of the most common acute complications of diabetes management.  
If severe it may result in hospital presentation, cardiovascular compromise, neurological 
dysfunction and even death.   
 
In the current project we will aim to examine trends in hypoglycemic agent drug use, 
demographics, comorbidities and hospital encounters for hypoglycemia in a cohort of 
adult diabetic patients from 2002 until 2013. To our knowledge such a detailed 
examination has not been carried out in our region previously.  
 
We anticipate that this project will help to provide insight into the changing diabetes 
population and their disease complications and help to improve the care of patients with 
this disease. 
 
Study Design Time series analysis 
List of Datasets Used 
RPDB (April 2002 to March 2013) 
 
ODB  (April 2001 to March 2013) 
Population 
 Age 65+ 
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Is druglist with DIN & DCLASS provided in Appendix? 
 Yes  
 
 
CIHI-DAD (April 1997 to March 2013) 
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or ‘AT’) 
 
Diagnosis Type (dxtype) 
  All (alldx) 
 
OHIP (April 1997 to March 2013) 
Claim Type 
 Nonlab 
 Lab 
 
Codes 
 Fee codes 
 Diagnostic codes 
 
NACRS (April 1997 to March 2013) 
Source 
 Emergency Department visits 
Include planned visits 
No 
Include suspected/questionable diagnoses? 
 No 
 
Gamma-Dynacare (April 2001-March 2013) 
Dataset 
 Southwestern Ontario 
 All of Ontario 
 
Type of test 
 Serum creatinine ‘/home/sdixon/data/GD/fullSCr’ 
 Hemoglobin A1C – test number 093D 
 
CERNER (April 2001-March 2012) 
File name: /ices/CDP/cerner/cerner_apr99_dec10.sas7bdat 
Type of test 
 Serum creatinine (Test_Done=”A”) 
 Hemoglobin A1C (Test Done=”B”) 
 
Hospital Stay 
 Inpatient  
 Emergency Room  
 Outpatient 
 
ODD (April 2002-March 2013) 
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Defining the Cohort 
Cohort Inclusion/ 
Denominator (for 
each study 
interval)  
For each 3 month interval, identify patients  with diabetes as defined by the Ontario Diabetes 
Database)    
 
 
See Appendix C and D for variable definitions 
Exclusions (to be 
applied during 
each study 
interval) 
 
1. Missing or invalid IKN 
2. Missing age or sex 
3. Invalid ages (negative ages or age >105) 
4. Death on or before the beginning of the study interval 
5. Non Ontario residents (individuals without the RPDB variable “prdcddablk” beginning 
with “35”) 
6. Age ˂66 years at the beginning of the study interval 
 
Time Frame Definitions 
 
 
 
 
 
 
Accrual Start/End Dates April 1, 2002-March 31, 2013 
 
Study intervals The 11 year (fiscal year) study will be divided into 44 intervals (each interval will be 
3 months in duration) 
 
Thus, each fiscal year will be divided into 4 quarters, defined by calendar months 
Quarter 1: April, May, June 
Quarter 2: July, August, September 
Quarter 3: October November December 
Quarter 4: January February March 
Look back Window(s) 1 year for baseline medications 
5 years for comorbidities 
1 year for laboratory data 
1 year for investigations 
 
Variable Definitions 
Main Exposure/ 
Numerator  
Users of at least one of the following study hypoglycemic agents during the study interval  
-Insulin 
-Acetohexamide 
-Chlorpropamide 
-Tolbutamide 
Observation Window 
140 
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-Glyburide 
-Gliclazide 
-Glimepiride 
-Repaglinide 
-Nateglinide 
-Pioglitazone 
-Rosiglitazone 
-Metformin 
-Acarbose 
-Sitagliptin 
-Saxagliptin 
-Sitagliptin-Metformin 
 
*See Appendix B and C for drug list and DCLASS definitions 
 
Baseline 
Characteristics 
(determine at the 
beginning of 3 
study quarters – 
April 1, 2002, 
April 1, 2007, 
April 1, 2012) 
We will determine the baseline characteristics of to examine if they remain similar over time.  
1. Age 
2. Sex  
3. Income quintile  
4. Rural location 
 
In the previous 5 years, evidence of the following: 
1. Chronic kidney disease 
2. Chronic liver disease 
3. Cancer 
4. Retinopathy 
5. Neuropathy 
6. Dementia 
7. Stroke/TIA 
8. Cardiovascular disease (excluding angina) 
9. Congestive heart failure 
10. Peripheral vascular disease 
 
For those with evidence of an HbA1c test in the 1 year previous (Gamma Dynacare 
OR CERNER): 
1. Mean, SD, Median, IQR HbA1c 
*Note if multiple HbA1c tests for an individual, use the most recent value 
 
In the previous 1 year: 
1. Mean, SD, median, IQR number of HbA1c tests 
2. Mean, SD, median, IQR number cholesterol tests 
3. Mean, SD, median, IQR number of creatinine tests 
4. N (%) with at least one major eye exam/ophthalmology assessment 
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*See Appendix A for sample tables, B for drug lists and C and D for variable definitions 
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Outline of Analysis Plan 
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1. Cohort creation 
- Apply inclusion and exclusion criteria during each interval to determine denominator for each interval 
(Sample Table 1) 
       2. Prescriptions 
            -Determine drug use for each interval (ie numerator).  Examine this by individual DCLASS     
            (Sample Table 2), number of hypoglycemic agent drugs prescribed (Sample Table 3), number of  
            NEW drug users (Sample Table 4) where NEW hypoglycemic agent users are those with no  
            evidence of ANY study hypoglycemic agent prescription in the previous 1 year 
-For NEW hypoglycemic agent users, examine also the number of hypoglycemic agent drugs prescribed 
during the interval (Sample Table 13) 
  
-Notes: For those prescribed sitagliptin-metformin combination, count a script for each DCLASS 
separately (ie. patient prescribed sitagliptin-metformin will have evidence of a prescription for both 
sitagliptin and for metformin) 
For calculation of general drug prescription rate, make denominator those prescribed hypoglycemic agents 
rather than the entire diabetic population (see Table 2 amendments) 
 
-For insulin users, examine number of other hypoglycemic agents prescribed (Table 11) 
-For those on insulin combination therapy (ie evidence of insulin and at least 1 other hypoglycemic agent 
during the interval) show rates of other DCLASS prescriptions (Table 12) 
 
2. Baseline characteristics Show number and proportion with the characteristics listed in Appendix C at the 
beginning of 3 study intervals (April 1, 2002, April 1, 2007, April 1, 2012)  for all diabetics (Table 6), for 
those prescribed at least one hypoglycemic agent (Table 9), and for NEW hypoglycemic agent users (Table 
10) 
 
3. Hypoglycemia 
Examine hospital encounters for hypoglycemia for each study interval.  Show the total number of 
hypoglycemic events during each interval (Sample Table 7) 
For the calculation of hypoglycemia rate, change denominator to those prescribed any hypoglycemic drug 
during the interval rather than the entire diabetic population  
*Note: Definitions of hypoglycemic events outlined in Appendix D 
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Appendix 
Appendix A – Sample Tables 
Trends Tables.xlsx
 
Appendix B – Drug Lists 
Trends Druglist.xlsx
 
Appendix C – Variable Definitions 
 
TrendsBaselines.txt
 
Appendix D – Variable Tables 
 
Table 1. Denominator Definition 
 
Characteristic Dataset Used Other details 
Diabetes with at least one 
hypoglycemic agent prescription 
(ie. diabetes drug users) 
ODD 
ODB 
 
 
 
Table 2: Study Medications 
Medication Name DCLASS 
Insulin S_INS 
Glyburide S_GLY 
Gliclazide S_GLI 
Repaglinide S_REP 
Metformin S_MET 
Pioglitazone S_PIO 
Rosiglitazone S_ROS 
Acarbose S_ACA 
Sitagliptin -Metformin S_SIM 
Sitagliptin S_SIT 
Saxagliptin S_SAX 
Tolbutamide S_TOL 
Acetohexamide S_ACT 
Chlorpropamide S_CHL 
Glimepiride S_GLM 
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Nateglinide S_NAT 
 
Table 3. Baseline Characteristics 
Characteristic Dataset Used Other details 
Year of index date 
  
Age RPDB Mean, SD, Median, IQR, 66-69, 
70-74, 75-79, 80-84, 85-89, ≥90 
Sex RPDB  
Income quartile PSTLYEAR 
%getdemo 
1, 2, 3, 4, 5, missing 
Residential status PSTLYEAR 
%get demo 
Rural, urban, missing 
CKD CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
NACRS  
Source 
 Emergency Department visits 
Include planned visits 
 No 
 
OHIP  
Claim Type 
 NONLAB 
 
For main cohort only 
Report as N (%) 
Retinopathy CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
NACRS  
Source 
 Emergency Department visits 
Include planned visits 
 No 
 
OHIP  
Claim Type 
 NONLAB 
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Dementia CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
NACRS  
Source 
 Emergency Department visits 
Include planned visits 
 No 
 
OHIP  
Claim Type 
 NONLAB 
 
Report as N (%) 
Liver Disease CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
NACRS  
Source 
 Emergency Department visits 
Include planned visits 
 No 
 
OHIP  
Claim Type 
 NONLAB 
Report as N (%) 
Coronary artery disease (excluding 
angina) 
CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
NACRS  
Source 
 Emergency Department visits 
Include planned visits 
 No 
 
Report as N (%) 
147 
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OHIP  
Claim Type 
 NONLAB 
 
Stroke/TIA CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
NACRS  
Source 
 Emergency Department visits 
Include planned visits 
 No 
 
OHIP  
Claim Type 
 NONLAB 
 
Report as N (%) 
Peripheral Vascular Disease CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
NACRS  
Source 
 Emergency Department visits 
Include planned visits 
 No 
 
OHIP  
Claim Type 
 NONLAB 
Report as N (%) 
Cancer CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
NACRS  
Source 
Report as N (%) 
148 
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 Emergency Department visits 
Include planned visits 
 No 
 
OHIP  
Claim Type 
 NONLAB 
 
Neuropathy CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
NACRS  
Source 
 Emergency Department visits 
Include planned visits 
 No 
 
OHIP  
Claim Type 
 NONLAB 
 
Report as N (%) 
CHF CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or 
‘AT’) 
Include suspected/questionable 
diagnoses? 
 No 
 
NACRS  
Source 
 Emergency Department visits 
Include planned visits 
 No 
 
OHIP  
Claim Type 
 NONLAB 
 
Report as N (%) 
149 
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HbA1c value Gamma-Dynacare  
Dataset 
 Southwestern Ontario 
 All of Ontario 
 
Type of test 
 Hemoglobin A1C – test number 
093D 
 
CERNER  
File name: 
/ices/CDP/cerner/cerner_apr99_dec
10.sas7bdat 
Type of test 
 Hemoglobin A1C (Test 
Done=”A”) 
 
Hospital Stay 
 Inpatient  
 Emergency Room  
 Outpatient 
 
Report as mean, SD, median, IQR 
HbA1c test OHIP 
Claim Type 
 All 
Code Types 
 Feecodes 
Report as mean, SD, median, IQR 
Cholesterol test OHIP 
Claim Type 
 All 
Code Types 
 Feecodes 
Report as mean, SD, median, IQR 
Creatinine test OHIP 
Claim Type 
 All 
Code Types 
 Feecodes 
Report as mean, SD, median, IQR 
Glucose test OHIP 
Claim Type 
 All 
Code Types 
 Feecodes 
Report as mean, SD, median, IQR 
Major eye exam/optho assessment OHIP 
Claim Type 
 All 
Code Types 
 Feecodes 
Report as N(%) 
 
150 
 
 
150
Curriculum Vitae 
 
Name:   Kristin Clemens 
 
Post-secondary  Western University 
Education and  London, Ontario, Canada 
Degrees:   2000-2004 BSc Biology 
 
Western University 
London, Ontario, Canada 
2004-2008 MD 
 
Western University 
London, Ontario, Canada 
2008-2011 Internal Medicine Residency 
 
Western University 
London, Ontario, Canada 
2011-2013 Endocrinology and Metabolism Fellowship 
 
Western University 
London, Ontario, Canada 
2014-Present Research Fellow Clinical Investigator Program/ 
ICES Faculty Scholars Program 
 
Western University 
London, Ontario, Canada 
2014-Present MSc Candidate Epidemiology 
 
 
Honours and   First Poster Prize Diabetes Research Day – London Ontario 
Awards:   2014 
 
PSI Foundation Resident Research Prize 
2014 
 
Class of 55 Prize 
2008 
 
JB Campbell Scholarship in Medicine 
2008 
 
Gold Medal Biology 
2004 
151 
 
 
151
 
Frederick N Lewis Prize 
2002 
 
Dean’s List Biology 
2000-2004 
 
 
Publications: 
1.Clemens KK, McArthur E, Dixon SN, Fleet JL, Hramiak I, Garg AX. The 
hypoglycemic risk of glyburide (glibenclamide) compared with modified release 
gliclazide. Can J Diabetes. 2015 Mar 31. pii: S1499-2671(15)00027-1. doi: 
10.1016/j.jcjd.2015.01.001. [Epub ahead of print] 
 
2. Clemens KK, McArthur E, Fleet JL, Hramiak I, Garg AX.  The risk of pancreatitis 
with sitagliptin therapy in older adults: a population-based cohort study.  CMAJ Open 
2015; 3: E172-181. 
 
3. Shih AW, Weir MA, Clemens KK, Yao Z, Gomes T, Mamdani MM, Juurlink DN, 
Hird A, Hodsman A, Parikh CR, Wald R, Cadarette SM, Garg AX.  Oral bisphosphonate 
use in the elderly is not associated with acute kidney injury.  Kidney Int. 2012; 82(8): 
903-8. 
 
4. Clemens K, Van Uum S. A pituitary mass as consequence of a decimal error in 
levothyroxine dose.  CMAJ. 2012; 184: 210. 
 
5. Kitchlu A, Clemens K, Gomes T, Hackam DG, Juurlink DN, Mamdani M, Manno M, 
Oliver MJ, Quinn RR, Suri RS, Wald R, Yan AT, Garg AX.  Beta blockers and 
cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada.  
Nephrology Dialysis Transplantation. 2011; 27(4): 1591-8. 
 
6. Clemens K, Payne W, Van Uum SH.  Central hypothyroidism.  Canadian Family 
Physician. 2011; 57: 677-680. 
 
7. Clemens KK, Boudville N, Dew MA, Geddes C, Gill JS, Jassal V, Klarenbach S, 
Knoll G, Muirhead N, Prasad GV, Storsley L, Treleaven D, Garg A; Donor Nephrectomy 
Outcomes Research (DONOR) Network.  The long term quality of life of living kidney 
donors: a multicentre cohort study.  American Journal of Transplantation. 2011; 11: 463-
469. 
 
152 
 
 
152
8. Moody EM, Clemens KK, Storsley L, Waterman A, Parikh CR, Garg AX; Donor 
Nephrectomy Outcomes Research (Donor) Network.  Improving online information for 
potential living kidney donors. Kidney International. 2007; 71: 1062-70.  
 
9.  Clemens KK, Thiesen-Philbrook H, Parikh CR, Yang RC, Karley ML, Boudville N, 
Ramesh Prasad GV, Garg AX; Donor Nephrectomy Outcomes Research (Donor) 
Network.  Psychosocial health of living kidney donors: a systematic review. American 
Journal of Transplantation. 2006; 6: 2965-77.  
 
 
